

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 3176181 T3**

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **C 07 K 16/28 (2006.01)** **A 61 K 39/395 (2006.01)** **A 61 P 35/00 (2006.01)**
A 61 P 37/04 (2006.01) **C 07 K 19/00 (2006.01)** **C 12 N 1/21 (2006.01)**
C 12 N 5/10 (2006.01) **C 12 N 15/13 (2006.01)** **C 12 N 15/63 (2006.01)**
G 01 N 33/577 (2006.01)
- (45) Oversættelsen bekendtgjort den: **2021-03-08**
- (80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2020-12-23**
- (86) Europæisk ansøgning nr.: **15827441.5**
- (86) Europæisk indleveringsdag: **2015-07-31**
- (87) Den europæiske ansøgnings publiceringsdag: **2017-06-07**
- (86) International ansøgning nr.: **CN2015085721**
- (87) Internationalt publikationsnr.: **WO2016015675**
- (30) Prioritet: **2014-08-01 CN 201410377352**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV
MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Akeso Biopharma Inc., 6 Shennong Boulevard , Torch Developmental Zone, Zhongshan,
Guangdong 528437, Kina**
- (72) Opfinder: **LI, Baiyong, 6 Shennong Blvd, Torch Developmental Zone, Zhongshan, Guangdong 528437, Kina
XIA, Yu, 6 Shennong Blvd, Torch Developmental Zone, Zhongshan, Guangdong 528437, Kina
WANG, Zhongmin, 6 Shennong Blvd, Torch Developmental Zone, Zhongshan, Guangdong 528437, Kina
ZHANG, Peng, 6 Shennong Blvd, Torch Developmental Zone, Zhongshan, Guangdong 528437, Kina
PANG, Xinghua, 6 Shennong Blvd, Torch Developmental Zone, Zhongshan, Guangdong 528437, Kina**
- (74) Fuldmægtig i Danmark: **Patrade A/S, Ceresbyen 75, 8000 Århus C, Danmark**
- (54) Benævnelse: **ANTI-CTLA4 MONOKLONAL ANTISTOF ELLER ANTIGENBINDENDE FRAGMENT DERAFT,
MEDICINAL SAMMENSÆTNING OG ANVENDELSE**
- (56) Fremdragne publikationer:
WO-A1-2012/038606
WO-A1-2012/120125
CN-A- 1 328 571
CN-A- 101 074 264
CN-A- 103 221 544
CN-A- 103 547 595
US-B1- 6 682 736
US-B1- 6 984 720
**FRANSEN MARIEKE F ET AL: "Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8(+) T-Cell-
Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects", CLINICAL CANCER RESEARCH, vol.**

Fortsættes ...

19, no. 19, October 2013 (2013-10), pages 5381-5389, XP009503302,
 MARIEKE FRANSEN ET AL: "Local immunomodulation for cancer therapy: Providing treatment where needed",
 ONCOIMMUNOLOGY, vol. 2, no. 11, 1 November 2013 (2013-11-01), pages e26493-1, XP055245571, DOI:
 10.4161/onci.26493 & F. STEPHEN HODI ET AL: "Improved Survival with Ipilimumab in Patients with Metastatic
 Melanoma", NEW ENGLAND JOURNAL OF MEDICINE, vol. 363, no. 8, 19 August 2010 (2010-08-19), pages 711-
 723, XP055015428, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1003466
 ALEXANDER M. MENZIES ET AL: "Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4
 antibodies and beyond", EUROPEAN JOURNAL OF CANCER, vol. 49, no. 15, 1 October 2013 (2013-10-01),
 pages 3229-3241, XP055203734, ISSN: 0959-8049, DOI: 10.1016/j.ejca.2013.06.027
 T DU ET AL: "Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating
 factor or anti-CTLA4 antibody for the treatment of cancers", CANCER GENE THERAPY, vol. 21, no. 8, 18 July
 2014 (2014-07-18), pages 340-348, XP055214039, ISSN: 0929-1903, DOI: 10.1038/cgt.2014.34
 IRA MELLMAN ET AL: "Cancer immunotherapy comes of age", NATURE, vol. 480, no. 7378, 1 January 2011
 (2011-01-01), pages 480-489, XP055054665, ISSN: 0028-0836, DOI: 10.1038/nature10673
 HARDCASTLE JAYSON J ET AL: "Modulation of Innate Immunity with the Anti-CTLA4 Antibody Ipilimumab (Ipi)
 in Measles Virotherapy for Glioblastoma", MOLECULAR THERAPY, vol. 21, no. Suppl. 1, June 2013 (2013-06) ,
 page S9, XP009503292, & 16TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-GENE-AND-CELL-
 THERAPY (ASGCT); SALT LAKE CITY, UT, USA; MAY 15 -18, 2013
 MAKI ROBERT G ET AL: "A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma",
 SARCOMA, 2013, XP009503293,
 CALABRÃŁ LUANA ET AL: "CTLA4 blockade in mesothelioma: finally a competing strategy over
 cytotoxic/target therapy?", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG,
 vol. 64, no. 1, 19 September 2014 (2014-09-19), pages 105-112, XP035417406, ISSN: 0340-7004, DOI:
 10.1007/S00262-014-1609-9 [retrieved on 2014-09-19]
 KUN SHAO ET AL: "Nanoparticle-Based Immunotherapy for Cancer", ACS NANO, vol. 9, no. 1, 27 January 2015
 (2015-01-27), pages 16-30, XP055380561, US ISSN: 1936-0851, DOI: 10.1021/nn5062029

DESCRIPTION

Technical field

[0001] The present invention belongs to the fields of tumor therapy and molecular immunology. The present invention relates to an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof, encoding sequences thereof and use in methods of diagnosis, prevention, therapy and/or adjuvant therapy using the same.

Technical background

[0002] Cytotoxic T lymphocyte associated antigen 4 (abbreviated as CTLA4) has very close relationship with the CD28 molecule in gene structure, chromosome location, sequence homology and gene expression. Both of them are receptors for the co-stimulative molecule B7, mainly expressed on the surface of activated T cells. However, as co-stimulating signal of lymphocyte activation, CTLA4 has opposite function to CD28. After binding to B7, CTLA4 can inhibit the activation of mouse and human T cells, playing a negative regulating role in the activation of T cells.

[0003] CTLA4 mAbs or CTLA4 ligands can prevent CTLA4 from binding to its native ligands, thereby blocking the transduction of the T cell negative regulating signal by CTLA4 and enhancing the responsivity of T cells to various antigens. In this aspect, results from in vivo and in vitro studies are substantially in concert. At present, there are some CTLA4 mAbs (10D1, 11.2.2) being tested in clinical trials for treating prostate cancer, bladder cancer, colorectal cancer, cancer of gastrointestinal tract, liver cancer, malignant melanoma, etc (CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Grosso JF., Jure-Kunkel MN., Cancer Immun. 2013; 13:5. Epub 2013 Jan 22; US 6984720 B1; and US 6682736 B1). Among them, 10D1 and 11.2.2 are regarded as among those anti-CTLA4 monoclonal antibodies having best effects.

[0004] Interleukin 2 (IL-2) is produced by T cells. It is a growth factor regulating a subgroup of T cells. It is also an important factor modulating immune response. It can promote and activate the expansion of B cells, and involves in antibody reaction, hematopoiesis and tumor surveillance. Recombinant human IL-2 has been approved by US FDA for the treatment of malignant tumors (including melanoma, kidney tumor, etc). It is also under clinical studies of treating chronic viral infection (Pharmacologic administration of interleukin-2. Chavez, A.R., et al., Ann N Y Acad Sci, 2009. 1182: 14-27).

[0005] As important factors affecting the function of T cells, CTLA4 and CTLA4 mAbs can produce specific therapeutic effect on diseases by interfering with the immune microenvironment in the body. They have high efficacy and remedy the deficiency of traditional

medication, opening a novel pathway of gene therapy. CTLA4 and CTLA4 mAbs are being tested in experiments and various stages of clinical trials. For example, in autoimmune diseases, they effectively inhibited airway hyperresponsiveness in an animal model of asthma, prevented the development of rheumatic diseases, mediated immune tolerance to an allograft in the body, and the like. On the other hand, although biological gene therapy has not shown any adverse effect in short term clinical trials, attention should be paid to the potential effect after long term application. For example, excessive blockade of CTLA4-B7 signaling by CTLA4 mAbs may result in the development of autoimmune diseases. As antibodies can specifically bind to their ligands and induce the lysis of target cells or block the progress of pathology, development and utilization of drugs based on antibodies, especially humanized antibodies have important significance in the clinical treatment of malignant tumors and other immune diseases in humans.

[0006] At present, there is yet a need to develop novel antibodies blocking the binding of CTLA4 to B7, and their humanized antibodies.

Summary of the invention

[0007] After intensive studies and creative works by the inventors, recombinant CTLA4 was expressed using a mammal cell expression system, and used as the antigen to immune mice. Hybridoma cells were obtained by fusing the mouse splenic cells with myeloma cells. After screening a great number of samples by the inventors, a hybridoma cell line capable of secreting and producing a specific monoclonal antibody which specifically binds CTLA4 and can block the binding of CTLA4 to B7 very effectively, was obtained. Furthermore, humanized antibodies were generated. Thus, the following inventions are provided.

[0008] The present invention provides an antibody or antigen binding fragment thereof that binds to human CTLA4, selected from the group consisting of:

1. (a) an antibody or antigen binding fragment thereof comprising a heavy chain variable region of SEQ ID NO: 14 and a light chain variable region of SEQ ID NO: 16; and
2. (b) an antibody or antigen binding fragment thereof comprising a heavy chain variable region of SEQ ID NO: 14 and a light chain variable region of SEQ ID NO: 16, wherein in SEQ ID NO: 14 at position 18, the methionine can be substituted for an amino acid selected from the group consisting of: leucine, valine, isoleucine, and alanine.

[0009] The present invention further provides one or more isolated nucleic acid molecules encoding an antibody or antigen binding fragment of the invention, specifically wherein the one or more isolated nucleic acid molecules have the nucleotide sequence as set forth in SEQ ID NO: 13 or SEQ ID NO: 15.

[0010] The present invention further provides the antibody or antigen binding fragment thereof of the invention for use in a method of treating cancer, such as melanoma, kidney tumor/renal tumor, prostate cancer, bladder cancer, colorectal cancer, cancer of gastrointestinal tract, and/or liver cancer/hepatic cancer in a human subject.

[0011] The present invention further provides the antibody or antigen binding fragment thereof of the invention for use in a method of treating lymphoma.

[0012] The present invention further provides an *in vitro* method comprising the step of administering to cells an effective amount of the antibody or antigen binding fragment thereof of the invention, wherein the method is selected from the following:

1. (a) a method of detecting the level of CTLA4 in a sample,
2. (b) a method of blocking the binding of human CTLA4 to human B7,
3. (c) a method of regulating the activity of human CTLA4 or the level of human CTLA4,
4. (d) a method of relieving the immunosuppression on the body by human CTLA4,
5. (e) a method of activating T lymphocytes, or
6. (f) a method of increasing the expression of IL-2 in T lymphocytes.

[0013] One aspect relates to a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody comprises the complementary determining regions (CDR's) selected from the following:

HCDR1 comprising the amino acid sequence of SEQ ID NO: 27,

HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and

HCDR3 comprising the amino acid sequence of SEQ ID NO: 29;

and/or

LCDR1 comprising the amino acid sequence of SEQ ID NO: 30,

LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and

LCDR3 comprising an amino acid sequence selected from SEQ ID NO: 32, SEQ ID NO: 33, and SEQ ID NO: 34.

[0014] The monoclonal antibody or antigen binding fragment thereof according to any one of the aspects of the present disclosure, wherein the amino acid sequence of the heavy chain variable region (VH) of the monoclonal antibody is selected from SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, and SEQ ID NO: 18;

and/or

the amino acid sequence of the light chain variable region (VL) of the monoclonal antibody is selected from SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 24.

[0015] The monoclonal antibody or antigen binding fragment thereof according to any one of the aspects of the present disclosure, wherein the monoclonal antibody comprises

1. (1) VH as set forth in SEQ ID NO: 6 and VL as set forth in SEQ ID NO: 8;
2. (2) VH as set forth in SEQ ID NO: 10 and VL as set forth in SEQ ID NO: 12;
3. (3) VH as set forth in SEQ ID NO: 14 and VL as set forth in SEQ ID NO: 16;
4. (4) VH as set forth in SEQ ID NO: 18 and VL as set forth in SEQ ID NO: 20;
5. (5) VH as set forth in SEQ ID NO: 14 and VL as set forth in SEQ ID NO: 22; or
6. (6) VH as set forth in SEQ ID NO: 14 and VL as set forth in SEQ ID NO: 24.

[0016] In the present disclosure, the above groups (1) to (6) show the amino acid sequences of the heavy chain variable region and light chain variable region of 8D2/8D2(Re), 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17, respectively.

[0017] Specifically, the methionine (Met) at position 18 in SEQ ID NO: 6, SEQ ID NO: 10, and SEQ ID NO: 14 is independently substituted with an amino acid selected from the following: Leucine (Leu), Valine (Val), Isoleucine (Ile), or Alanine (Ala).

[0018] Therapeutic drugs based on antibodies, especially monoclonal antibodies (MAB) have achieved excellent efficacy in the treatment of several diseases. The traditional method to obtain such therapeutic antibody is immunizing an animal with an antigen, obtaining antibodies against the antigen from the immunized animal, or improving an antibody having low affinity to the antigen by affinity maturation. However, such method is time consuming and labor consuming, and often fails to target a specific epitope on the antigen.

[0019] Antigen binding is dependent on the variable regions of the light chain and heavy chain; the variable region of each chain comprises three hypervariable regions, also called complementarity determining region (CDR) (the heavy chain (H) comprises HCDR1, HCDR2 and HCDR3, and the light chain (L) comprises LCDR1, LCDR2 and LCDR3; for definition, see Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition (1991), Vol. 1-3, NIH Publication 91-3242, Bethesda Md).

[0020] The amino acid sequences of the CDRs in the monoclonal antibody sequences of the aspects (1) to (6) above were analyzed by technical means well known to those skilled in the art, e.g., by VBASE2 database analysis. The results are provided below.

(1) The amino acid sequences of the 3 CDRs of the heavy chain variable region are shown below:

HCDR1: GFTFSDNW	(SEQ ID NO: 27),
-----------------	------------------

HCDR2: IRNKPYNYET	(SEQ ID NO: 28),
HCDR3: TAQFAY	(SEQ ID NO: 29).

The amino acid sequences of the 3 CDRs of the light chain variable region are shown below:

LCDR1: ENIYGG	(SEQ ID NO: 30),
LCDR2: GAT	(SEQ ID NO: 31),
LCDR3: QNVLRSPFT	(SEQ ID NO: 32).

(2) The amino acid sequences of the 3 CDRs of the heavy chain variable region are shown below:

HCDR1: GFTFSDNW	(SEQ ID NO: 27),
HCDR2: IRNKPYNYET	(SEQ ID NO: 28),
HCDR3: TAQFAY	(SEQ ID NO: 29).

The amino acid sequences of the 3 CDRs of the light chain variable region are shown below:

LCDR1: ENIYGG	(SEQ ID NO: 30),
LCDR2: GAT	(SEQ ID NO: 31),
LCDR3: QNVLRSPFT	(SEQ ID NO: 32).

(3) The amino acid sequences of the 3 CDRs of the heavy chain variable region are shown below:

HCDR1: GFTFSDNW	(SEQ ID NO: 27),
HCDR2: IRNKPYNYET	(SEQ ID NO: 28),
HCDR3: TAQFAY	(SEQ ID NO: 29).

The amino acid sequences of the 3 CDRs of the light chain variable region are shown below:

LCDR1: ENIYGG	(SEQ ID NO: 30),
LCDR2: GAT	(SEQ ID NO: 31),
LCDR3: QNVLRSPFT	(SEQ ID NO: 32).

(4) The amino acid sequences of the 3 CDRs of the heavy chain variable region are shown below:

HCDR1: GFTFSDNW	(SEQ ID NO: 27),
HCDR2: IRNKPYNYET	(SEQ ID NO: 28),
HCDR3: TAQFAY	(SEQ ID NO: 29).

The amino acid sequences of the 3 CDRs of the light chain variable region are shown below:

LCDR1: ENIYGG	(SEQ ID NO: 30),
LCDR2: GAT	(SEQ ID NO: 31),
LCDR3: QNVLRSPFT	(SEQ ID NO: 32).

(5) The amino acid sequences of the 3 CDRs of the heavy chain variable region are shown

below:

HCDR1: GFTFSDNW	(SEQ ID NO: 27),
HCDR2: IRNKPYNYET	(SEQ ID NO: 28),
HCDR3: TAQFAY	(SEQ ID NO: 29).

The amino acid sequences of the 3 CDRs of the light chain variable region are shown below:

LCDR1: ENIYGG	(SEQ ID NO: 30),
LCDR2: GAT	(SEQ ID NO: 31),
LCDR3: QNVLSRHPG	(SEQ ID NO: 33).

(6) The amino acid sequences of the 3 CDRs of the heavy chain variable region are shown below:

HCDR1: GFTFSDNW	(SEQ ID NO: 27),
HCDR2: IRNKPYNYET	(SEQ ID NO: 28),
HCDR3: TAQFAY	(SEQ ID NO: 29).

The amino acid sequences of the 3 CDRs of the light chain variable region are shown below:

LCDR1: ENIYGG	(SEQ ID NO: 30),
LCDR2: GAT	(SEQ ID NO: 31),
LCDR3: QNVLSSRPG	(SEQ ID NO: 34).

[0021] The monoclonal antibody or antigen binding fragment thereof according to any one of the embodiments of the present invention, wherein the monoclonal antibody or antigen binding fragment thereof is selected from an Fab, an Fab', an F(ab')₂, an Fd, an Fv, a dAb, a complementarity determining region fragment, a single chain antibody (e.g., an scFv), a humanized antibody, a chimeric antibody, or a diabody.

[0022] The monoclonal antibody or antigen binding fragment thereof according to any one of the embodiments of the present invention, wherein the monoclonal antibody binds the CTLA4 protein with a K_D less than about 10⁻⁵ M, e.g., less than about 10⁻⁶ M, 10⁻⁷ M, 10⁻⁸ M, 10⁻⁹ M, or 10⁻¹⁰ M or less.

[0023] The monoclonal antibody or antigen binding fragment thereof according to any one of the embodiments of the present invention, wherein the monoclonal antibody comprises non-CDR regions, and said non-CDR regions are from an antibody of a species other than murine, e.g., a human.

[0024] The monoclonal antibody or antigen binding fragment thereof of the present invention is an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof that can specifically bind CTLA4.

[0025] The monoclonal antibody or antigen binding fragment thereof according to any one of the aspects of the present disclosure for use in the prevention and/or therapy and/or adjuvant therapy and/or diagnosis of a tumor; specifically, the tumor is selected from melanoma, kidney tumor/renal tumor, prostate cancer, bladder cancer, colorectal cancer, cancer of gastrointestinal tract, and liver cancer/hepatic cancer.

[0026] The monoclonal antibody according to any one of the embodiments of the present invention for use in:

blocking the binding of CTLA4 to B7,

regulating (e.g., down-regulating) the activity of CTLA4 or the level of CTLA4,

relieving the immunosuppression on the body by CTLA4, or

an agent activating T lymphocytes or increasing the expression of IL-2 in T lymphocytes.

[0027] Another aspect of the present disclosure relates to an isolated nucleic acid molecule, which comprises a nucleic acid sequence capable of encoding the heavy chain variable region of an antibody, wherein

the heavy chain variable region of the antibody comprises CDRs with the amino acid sequences of SEQ ID NOs: 27-29;

specifically, the heavy chain variable region of the antibody has the amino acid sequence as set forth in SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, or SEQ ID NO: 18;

more specifically, the nucleic acid molecule has the nucleotide sequence as set forth in SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, or SEQ ID NO: 17.

[0028] The present invention further provides isolated nucleic acid molecules, which encode the monoclonal antibody or antigen binding fragment thereof of the present invention. Such nucleic acid molecules can be isolated from the hybridoma cells, or obtained through recombinant technologies of gene engineering or methods of chemical synthesis.

[0029] A further aspect of the present disclosure relates to an isolated nucleic acid molecule, which comprises a nucleic acid sequence capable of encoding the light chain variable region of an antibodies, wherein

the light chain variable region of the antibody comprises

1. 1) CDRs with the amino acid sequences of SEQ ID NOs: 30-32;

2. 2) CDRs with the amino acid sequences of SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO: 33; or

3. 3) CDRs with the amino acid sequences of SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO: 34;

specifically, the light chain variable region of the antibody has the amino acid sequence as set forth in SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID

NO: 22, or SEQ ID NO: 24;

more specifically, the nucleic acid molecule has the nucleotide sequence as set forth in SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23.

[0030] A further embodiment of the present invention relates to a vector, which comprises the isolated nucleic acid molecule according to any one of the embodiments of the present invention. The vector of the present invention can be a cloning vector or an expression vector. In a preferred embodiment, the vector of the present invention is, for example, a plasmid, a cosmid, a bacteriophage, a coemid, or the like.

[0031] A further embodiment of the present invention relates to a host cell, which comprises the isolated nucleic acid molecule of any one of the embodiments of the present invention, or the vector according to the present invention. Such host cells include, but are not limited to, prokaryotic cells such as *E. coli* cells, and eukaryotic cells such as yeast cells, insect cells, plant cells, and animal cells (such as mammalian cells, including mouse cells, human cells, or the like). The cells of the present invention can also be a cell line, such as 293T cells.

[0032] A further aspect embodiment of the present invention relates to a method of preparing the monoclonal antibody or antigen binding fragment thereof according to any one of the embodiments of the present invention, the method comprising the steps of culturing the host cell of the present invention under suitable conditions and recovering the monoclonal antibody or antigen binding fragment thereof from the cell culture.

[0033] A further aspect relates to a conjugate, which comprises a monoclonal antibody or antigen binding fragment thereof and a conjugated moiety, wherein the monoclonal antibody is a monoclonal antibody or antigen binding fragment thereof according to any one of the embodiments of the present invention, and the conjugated moiety is a detectable label. Specifically, the conjugated moiety is a radioisotope, a fluorescent substance, a luminescent substance, a chromogenic substance, or an enzyme (e.g., horse radish peroxidase).

[0034] A further aspect of the present disclosure relates to a kit, which comprises the monoclonal antibody or antigen binding fragment thereof according to any one of the embodiments of the present invention, or the conjugate according to the present invention; specifically, the kit further comprises a second antibody, which specifically recognizes said monoclonal antibody or antigen binding fragment thereof; optionally, said second antibody further comprises a detectable label, e.g., a radioisotope, a fluorescent substance, a luminescent substance, a chromogenic substance, or an enzyme (e.g., horse radish peroxidase).

[0035] A further aspect of the present disclosure relates to use of the monoclonal antibody or antigen binding fragment thereof according to any one of the embodiments of the present

invention in the preparation of a kit for use in detecting the presence or level of CTLA4 in a sample.

[0036] A further aspect relates to a pharmaceutical composition, which comprises the monoclonal antibody or antigen binding fragment thereof according to any one of the embodiments of the present invention or the conjugate according to the present invention; optionally, it further comprises a pharmaceutically acceptable carrier and/or excipient.

[0037] A further aspect relates to use of the monoclonal antibody or antigen binding fragment thereof according to any one of the embodiments of the present invention or the conjugate according to the present invention in the preparation of a medicament for use in the prevention and/or therapy and/or adjuvant therapy and/or diagnosis of a tumor; specifically, the tumor is selected from melanoma, kidney tumor/renal tumor, prostate cancer, bladder cancer, colorectal cancer, cancer of gastrointestinal tract, and liver cancer/hepatic cancer.

[0038] A further aspect relates to use of the monoclonal antibody or antigen binding fragment thereof according to any one of the embodiments of the present invention or the conjugate according to the present invention in the preparation of a following agent:

an agent that detects the presence or level of CTLA4 in a sample,

an agent that blocks the binding of CTLA4 to B7,

an agent that regulates (e.g., down-regulates) the activity of CTLA4 or the level of CTLA4,

an agent that relieves the immunosuppression on the body by CTLA4,

an agent that activates T lymphocytes, or

an agent that increases the expression of IL-2 in T lymphocytes.

[0039] A further aspect relates to an in vivo or in vitro method comprising the step of administering to cells an effective amount of the monoclonal antibody or antigen binding fragment thereof according to any one of the embodiments of the present invention or the conjugate according to the present invention, wherein the method is selected from the following:

a method of detecting the presence or level of CTLA4 in a sample,

a method of blocking the binding of CTLA4 to B7,

a method of regulating (e.g., down-regulating) the activity of CTLA4 or the level of CTLA4,

a method of relieving the immunosuppression on the body by CTLA4,

a method of activating T lymphocytes, or

a method of increasing the expression of IL-2 in T lymphocytes.

[0040] Said methods can be used for diagnostic or therapeutic purposes, or non-diagnostic or non-therapeutic purposes (e.g., where the sample is a cell sample, rather than a sample from a patient).

[0041] A further aspect relates to a method of the prevention and/or therapy and/or adjuvant therapy and/or diagnosis of a tumor, comprising administering to a subject an effective amount of the monoclonal antibody or antigen binding fragment thereof according to any one of the aspects of the present disclosure or the conjugate according to the present invention; specifically, the tumor is selected from melanoma, kidney tumor/renal tumor, prostate cancer, bladder cancer, colorectal cancer, cancer of gastrointestinal tract, and liver cancer/hepatic cancer.

[0042] In the present invention, unless stated otherwise, scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the art. Moreover, procedures of cell culture, molecular genetics, nucleic acid chemistry, immunology used herein are the widely utilized methodologies in the relevant art. Meanwhile, for purpose of better understanding the present invention, the definitions and explanations of relevant terms are provided below.

[0043] As used herein, when reference is made to the amino acid sequence of the CTLA4 protein (Cytotoxic T-Lymphocyte Antigen 4), it includes the full length of the CTLA4 protein, or the extracellular fragment of CTLA4, CTLA4ECD (SEQ ID NO: 2), or a fragment comprising CTLA4ECD; it also includes a fusion protein of CTLA4ECD, e.g., a fragment fused to the Fc protein fragment of a mouse IgG (mFc) (SEQ ID NO: 3). However, as understood by those skilled in the art, a mutation or variation (including, but not limited to, substitution, deletion and/or addition) may be naturally produced in or artificially introduced into the amino acid sequence of the CTLA4 protein, without affecting its biological functions. Therefore, in the present invention, the term "CTLA4 protein" should include all such sequences, including the sequence as set forth in SEQ ID NO: 2, as well as its native or artificial variants. Furthermore, when reference is made to a sequence fragment of the CTLA4 protein, it not only includes a sequence fragment of SEQ ID NO: 2, but also includes the corresponding sequence fragments of its native or artificial variants.

[0044] As used herein, unless specifically stated, B7 refers to B7-1 and/or B7-2; and their specific protein sequences refer to the sequences known in the art. Reference can be made to the sequences disclosed in the literatures of the prior art or GenBank, e.g., B7-1 (CD80, NCBI Gene ID: 941), B7-2 (CD86, NCBI Gene ID: 942).

[0045] As used herein, the term EC₅₀ refers to concentration for 50% of maximal effect, i.e., the concentration causing 50% of the maximal effect.

[0046] As used herein, the term "antibody" refers to an immunoglobulin molecule which generally consists of two pairs of polypeptide chains (each pair has a "light" (L) chain and a "heavy" (H) chain). Antibody light chains can be classified as κ and λ light chain. Heavy chains can be classified as μ , δ , γ , α or ϵ , and the isotypes of antibody are defined as IgM, IgD, IgG, IgA and IgE, respectively. Within a light chain and heavy chain, a variable region and a constant region are joined via a "J" region of about 12 or more amino acids, and heavy chain further comprises a "D" region of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (V_H) and a heavy chain constant region (C_H). The heavy chain constant region consists of 3 domains (C_{H1} , C_{H2} and C_{H3}). Each light chain consists of a light chain variable region (V_L) and a light chain constant region (C_L). The light chain constant region consists of a C_L domain. The constant region of antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component of the classical complement system (C1q). V_H and V_L regions can further be subdivided into regions having high variability (referred to as complementarity determining region (CDR)), interspersed with regions called framework regions (FR) which are relatively conserved. Each V_H or V_L consists of 3 CDRs and 4 FRs, arranged by the following order from the amino terminal to the carboxy terminal: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions (V_H and V_L) of each pair of heavy chain / light chain form an antibody binding site, respectively. The assignment of amino acids to each region or domain follows the definition provided in Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917; Chothia et al. (1989) Nature 342: 878-883. The term "antibody" is not limited by any specific method for producing the antibody. For example, it includes, particularly, recombinant antibodies, monoclonal antibodies and polyclonal antibodies. Antibodies can be antibodies of different isotypes, e.g., IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibodies.

[0047] As used herein, the term "antigen binding fragment" of antibody refers to a polypeptide comprising a fragment of a full length antibody, which retains the ability to specifically bind to the antigen bound by the full length antibody, and/or to compete with the full length antibody for specifically binding to the antigen. It is also referred to as "antigen binding portion". Generally, see Fundamental Immunology, Ch. 7 (Paul, W., ed., Second Edition, Raven Press, N.Y. (1989)). Antigen binding fragments of antibodies can be produced by recombinant DNA technique or enzymatic or chemical cleavage of intact antibodies. In some cases, antigen binding fragments include Fab, Fab', F(ab')₂, Fd, Fv, dAb and complementarity determining region (CDR) fragment, single chain antibody (e.g., scFv), chimeric antibody, diabody and such polypeptides which comprises at least a portion of the antibody sufficient to confer the ability of specific antigen binding to the polypeptide.

[0048] As used herein, the term "Fd fragment" refers to an antibody fragment consisting of the V_H and C_{H1} domains; the term "Fv fragment" refers to an antibody fragment consisting of the V_L and V_H domains of a single arm of antibody; the term "dAb fragment" refers to an antibody

fragment consisting of the V_H domain (Ward et al., Nature 341: 544-546 (1989)); the term "Fab fragment" refers to an antibody fragment consisting of the V_L , V_H , C_L and C_{H1} domains; and the term " $F(ab')_2$ fragment" refers to an antibody fragment comprising two Fab fragments connected by disulfide bridges on the hinge region.

[0049] In some cases, the antigen binding fragment of antibody is a single chain antibody (e.g., scFv), wherein the V_L and V_H domains pair to each other via a linker which enables production of a single polypeptide chain to form a mono-valent molecule (see, e.g., Bird et al., Science 242: 423-426 (1988) and Huston et al., Proc. Natl. Acad. Sci. USA 85: 5879-5883 (1988)). Such scFv molecule can have the general structure: NH_2-V_L -Linker- V_H-COOH or NH_2-V_H -Linker- V_L-COOH . Suitable linkers from the prior art consist of the repeated GGGGS amino acid sequence or its variants. For example, a linker having the amino acid sequence $(GGGGS)_4$ can be used, but its variants can also be used (Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6444-6448). Other linkers useful in the present invention are described in Alfthan et al. (1995) Protein Eng. 8: 725-731; Choi et al. (2001) Eur. J. Immunol. 31: 94-106; Hu et al. (1996) Cancer Res. 56: 3055-3061; Kipriyanov et al. (1999) J. Mol. Biol. 293: 41-56 and Roovers et al. (2001) Cancer Immunol.

[0050] In some cases, the antigen binding fragment of antibody is a diabody (a bivalent antibody), wherein the V_H and V_L domains are expressed on a single polypeptide chain. However, the linker exploited is too short that the two domains on the same chain cannot pair with each other, and are forced to pair with the complementary domain on another chain. By this way, two antigen binding sites are formed (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993) and Poljak R. J. et al., Structure 2: 1121-1123 (1994)).

[0051] Antigen binding fragments of antibodies (e.g., the above antibody fragments) can be obtained from given antibodies (e.g., the monoclonal antibodies 4B3, 13A10, 12B9, or 4H4 provided in the present invention) using conventional technologies which are known to those skilled in the art (e.g., recombinant DNA technique or enzymatic or chemical cleavage method), and can be screened for specificity in the same way as that of intact antibodies.

[0052] Herein, unless explicitly indicated in the context, when reference is made to the term "antibody", it not only includes intact antibodies, but also includes antigen binding fragments of antibodies.

[0053] As used herein, the terms "mAb" or "monoclonal antibody" refers to an antibody or antibody fragment from a population of highly homogenous antibody molecules, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations. Monoclonal antibodies are highly specific to a single epitope on the antigen. In contrast to monoclonal antibodies, polyclonal antibody preparations typically include at least two or more different antibodies recognizing different epitopes on the antigen. Monoclonal antibodies can generally be obtained using the hybridoma technique first described by Kohler et al. (Nature, 256: 495, 1975), or can be obtained using the recombinant

DNA technique (see US Patent 4,816,567, for example).

[0054] As used herein, a monoclonal antibody mentioned with a number is identical with the monoclonal antibody obtained from a hybridoma mentioned with the same number. For example, the monoclonal antibody 4B3 (or 13A10, 12B9 or 4H4) is identical to the antibody obtained from the hybridoma cell line 4B3 (or 13A10, 12B9 or 4H4) or its subclones or descendent cells.

[0055] As used herein, the term "chimeric antibody" refers to such an antibody, in which a portion of the light chain and/or heavy chain is derived from an antibody (which can be derived from a particular species or belong to a particular antibody class or subclass), while another portion of the light chain and/or heavy chain is derived from another antibody (which can be derived from an identical or different species or belong to an identical or different antibody class or subclass), as long as it retains the activity to bind to the target antigen (US Patent 4,816,567 awarded to Cabilly et al.; Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984)).

[0056] As used herein, the term "humanized antibody" refers to the antibody or antibody fragment obtained after replacing all or some CDRs of a human immunoglobulin (recipient antibody) with CDRs of a non-human antibody (donor antibody), wherein the donor antibody can be a non-human (e.g., mouse, rat or rabbit) antibody having the desired specificity, affinity or reactivity. Furthermore, some amino acid residues of the framework regions (FRs) of the recipient antibody can be replaced with corresponding amino acid residues of the non-human antibody or amino acid residues of other antibodies so as to further improve or optimize the performance of the antibody. For more details about humanized antibodies, see, e.g., Jones et al., Nature, 321: 522-525 (1986); Reichmann et al., Nature, 332: 323-329 (1988); Presta, Curr. Op. Struct. Biol., 2: 593-596 (1992); and Clark, Immunol. Today 21: 397-402 (2000).

[0057] As used herein, a "neutralizing antibody" refers to an antibody or antibody fragment that can remove or significantly reduce the virulence of the target virus (e.g., the ability to infect cells).

[0058] As used herein, the term "epitope" refers to the part on an antigen specifically bound by an immunoglobulin or antibody. In the art, "epitope" is also called "antigenic determinant". An epitope or antigenic determinant generally consists of the chemically active surface groups of the molecule, e.g., amino acid or carbohydrate compounds or sugar side chains, and generally has specific three-dimensional structural characteristics and specific charge characteristics. For example, an epitope generally comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive or inconsecutive amino acids in a distinct spatial conformation. It can be a "linear" or "conformational" epitope. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G. E. Morris, Ed. (1996). In a linear epitope, all the points of the interaction between the protein and the interacting molecule (e.g., antibody) are present along the primary amino acid sequence of the protein in a line. In a conformational epitope, the interacting points are present as spanning the amino acid residues of the protein which are

separate from each other.

[0059] As used herein, the term "isolated" means being obtained from the native state by artificial means. If an "isolated" substance or component occurs in the nature, it is likely that its natural environment has changed, or the substance has been isolated from the natural environment, or both. For example, unisolated polynucleotides or polypeptides naturally occur in a living animal in vivo, and identical polynucleotides or polypeptides of high purity isolated from such natural state are described as "isolated". The term "isolated" does not exclude mixture with artificial or synthetic substances, and does not exclude the presence of other impurities which do not affect the activities of the substance.

[0060] As used herein, the term "E. coli expression system" refers to an expression system consisting of E. coli (strain) and the vector, wherein E. coli (strain) is derived from strains commercially available, e.g., but not limited to GI698, ER2566, BL21(DE3), B834(DE3), and BLR(DE3).

[0061] As used herein, the term "vector" refers to a nucleic acid carrying tool into which a polynucleotide can be inserted. When a vector enables the expression of the protein encoded by the inserted polynucleotide, the vector is called expression vector. A vector can be introduced into a host cell by transformation, transduction or transfection, such that the genetic substance component carried by the vector is expressed in the host cell. Vectors are well known to those skilled in the art, including, but not limited to: plasmid; phagemid; cosmid; artificial chromosome, e.g., yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC); bacteriophage, e.g., λ phage or M13 phage as well as animal virus, and the like. Animal viruses which can be used as a vector, include, but not limited to, retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpes virus (e.g., herpes simplex virus), poxvirus, baculovirus, papilloma virus, papova virus (e.g., SV40). A vector can comprise several components for controlling the expression, including, but not limited to, promoter sequence, transcription initiation sequence, enhancer sequence, selection component and reporter gene. Moreover, a vector can also comprise replication initiation site.

[0062] As used herein, the term "host cell" refers to cells which can be used for introduction of a vector, including, but not limited to, prokaryotic cells such as E. coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cell or Sf9, or animal cells such as fibroblast, CHO cell, COS cell, NSO cell, HeLa cell, BHK cell, HEK 293 cell or human cell.

[0063] As used herein, the term "identity" is used to describe the sequence matching between two polypeptides or between two nucleic acids. When the corresponding positions in two sequences compared are occupied by the same base or amino acid monomer subunit (for example, the corresponding positions in two DNA molecules are both occupied by adenine, or the corresponding positions in two polypeptides are both occupied by lysine), the molecules are identical at that position. The "percent identity" between two sequences is a function of the

number of the matching positions shared by these two sequences divided by the number of the positions compared $\times 100$. For example, if 6 among 10 positions of two sequences match, these two sequences have 60% identity. For example, DNA sequences CTGACT and CAGGTT share 50% identity (3 among 6 positions match in total). Generally, two sequences are compared after alignment to generate maximal identity. For example, such alignment can be conveniently achieved using a computer program, e.g., the Align program (DNASTar, Inc.), by the method of Needleman et al. (1970) *J. Mol. Biol.* 48: 443-453. Furthermore, the algorithm of E. Meyers and W. Miller (*Comput. Appl. Biosci.*, 4: 11-17 (1988)) incorporated into the ALIGN program (version 2.0) can be used to determine the percent identity between two amino acid sequences, using the PAM120 weight residue table, a Gap length penalty of 12 and a gap penalty of 4. Moreover, the algorithm of Needleman and Wunsch (*J Mol Biol.* 48: 444-453 (1970)) incorporated into the GAP program of the GCG package (available at www.gcg.com) can be used to determine the percent identity between two amino acid sequences, using the Blossum 62 matrix or PAM250 matrix, a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

[0064] As used herein, the term "conservative substitution" refers to amino acid substitutions that do not disadvantageously affect or alter the essential properties of the protein/polypeptide comprising the amino acid sequence. For example, conservative substitutions can be introduced by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions include those wherein an amino acid residue is replaced with an amino acid residue having a similar side chain, e.g., a residue similar to the corresponding amino acid residue in terms of physics or function (e.g., having similar size, shape, charge, chemical properties, including the ability to form a covalent bond or hydrogen bond, or the like). Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids having a basic side chain (e.g., lysine, arginine and histidine), an acidic side chain (e.g., aspartic acid and glutamic acid), an uncharged polar side chain (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, and tryptophan), a non-polar side chain (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, and methionine), a beta-branched side chain (e.g., threonine, valine and isoleucine), and an aromatic side chain (e.g., tyrosine, phenylalanine, tryptophan, and histidine). Thus, it is preferred to replace the corresponding amino acid residue with another amino acid residue from the same side chain family. Methods of identifying amino acid conservative substitutions are well known in the art (see, e.g., Brummell et al., *Biochem.*, 32: 1180-1187 (1993); Kobayashi et al., *Protein Eng.* 12(10): 879-884 (1999); and Burks et al., *Proc. Natl. Acad. Sci. USA*, 94: 412-417 (1997)).

[0065] As used herein, the term "immunogenicity" refers to the ability to stimulate the body to generate specific antibodies or sensitize lymphocytes. It not only refers to the properties of the antigen which can stimulate specific immune cells so as to induce activation, proliferation and differentiation of the immune cells, and ultimately production of immune effector substances such as antibodies, and can sensitize lymphocytes, but also refers to the specific immune responses by the body's immune system to produce antibodies or sensitize T lymphocytes after the stimulation of the body by the antigen. Immunogenicity is the most important property

of the antigen. Whether an antigen can successfully induce immune response in a host depends on three factors: the nature of the antigen, the reactivity of the host and the manner of immunization.

[0066] As used herein, the term "specific binding" refers to the non-random binding reaction between two molecules, such as the reaction between an antibody and its targeted antigen. In some embodiments, an antibody specifically binding an antigen (or an antibody specific for an antigen) means the antibody binds the antigen with an affinity (K_D) less than about 10^{-5} M, e.g., less than about 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M, or 10^{-10} M or less.

[0067] As used herein, the term " K_D " refers to the dissociation equilibration constant of a particular antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The less the equilibration dissociation constant is, the tighter the antibody-antigen binding is and the higher the affinity between the antibody and antigen is. Generally, an antibody (e.g., the monoclonal antibodies 4B3, 13A10, 12B9, or 4H4 of the present invention) binds the antigen (e.g., the L1 protein) with a dissociation equilibration constant (K_D) less than about 10^{-5} M, e.g., less than about 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M, or 10^{-10} M or less, e.g., as determined using Surface Plasmon Resonance (SPR) on a BIACORE instrument.

[0068] As used herein, the terms "monoclonal antibody" and "mAb" have the same meaning, and can be used interchangeably. Also, the terms "polyclonal antibody" and "pAb" have the same meaning, and can be used interchangeably. Again, the terms "polypeptide" and "protein" have the same meaning, and can be used interchangeably. Furthermore, in the present invention, amino acids are generally represented by single-letter or three-letter abbreviations well known in the art. For example, alanine can be represented by A or Ala.

[0069] As used herein, the terms "hybridoma" and "hybridoma cell line" can be used interchangeably. Moreover, when reference is made to the term "hybridoma" or "hybridoma cell line", it also comprises the subclones and descendent cells of the hybridoma. For example, when reference is made to the hybridoma cell line 4B3, it also comprises the subclones and descendent cells of the hybridoma cell line 4B3.

[0070] As used herein, the term "pharmaceutically acceptable vector and/or excipient" refers to vector and/or excipient compatible to the subject and the active component in pharmacology and/or physiology, which are well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and include but not limited to: pH adjusting agent, surfactant, adjuvant, ionic intensity enhancer. For example, pH adjusting agent includes but not limited to phosphate buffer; surfactant includes but not limited to cationic, anionic or nonionic surfactant, e.g., Tween-80; and ionic intensity enhancer includes but not limited to sodium chloride.

[0071] As used herein, the term "adjuvant" refers to non-specific immune enhancer, which can

enhance the immune response of the body to the antigen or change the type of the immune response when delivered together with an antigen or in advance into the body. There are many adjuvants, including but not limited to aluminum adjuvant (e.g., aluminum hydroxide), Freund's adjuvant (e.g., complete Freund's adjuvant and incomplete Freund's adjuvant), *Corynebacterium parvum*, lipopolysaccharide, cytokine, and the like. Freund's adjuvant is the most commonly used one in animal trials at present, and aluminum hydroxide is the widely used one in clinical experiments.

[0072] As used herein, the term "effective amount" refers to an amount sufficient to achieve or at least partially achieve the desired effects. For example, prophylactically effective amount for a disease (e.g., a disease associated with excessive binding of CTLA4 to B7 or CTLA4 activity such as tumor) refers to an amount sufficient to prevent, arrest, or delay the development of a disease (e.g., a disease associated with excessive binding of CTLA4 to B7 or CTLA4 activity such as tumor); and therapeutically effective amount for a disease refers to an amount sufficient to cure or at least partially arrest a disease and its complications in a patient suffering from the disease. It is well within the skills of those skilled in the art to determine such effective amount. For example, a therapeutically effective amount will depend on the severity of the disease to be treated, the general status of the immune system of the patient, the general status of the patient, e.g., age, body weight and sex, administration mode of the agent, other therapies administered simultaneously, and the like.

Beneficial effects of the invention

[0073] The monoclonal antibody 8D2 and its humanized antibodies of the present invention can specifically bind to CTLA4 very well. Among them, the antibodies 8D2 and 8D2(Re) bind to the murine CTLA4 antigen at a binding efficiency better than the control antibodies 10D1 (Alan J. Korman, Edward L. Halk, et al., HUMAN CTLA-4 ANTIBODIES, United State Patent No. US 6984720 B1) and 11.2.1 (Douglas Charles Hanson, Mark Joseph Neveu, et al., Human monoclonal antibodies to CTLA-4, United State Patent No. US 682736 B1). The humanized antibody 8D2H1L1 binds to the murine CTLA4 antigen at a binding efficiency better than the control antibody 10D1, and comparable to 11.2.1. The humanized antibody 8D2H2L2 binds to the human CTLA4 antigen at a binding efficiency comparable to 10D1. The humanized antibodies 8D2H2L2 and 8D2H3L3 bind to the monkey CTLA4 antigen at a binding efficiency comparable to 10D1. The antibodies 8D2H2L15 and 8D2H2L17 bind to the human CTLA4 antigen at a binding efficiency better than the control antibodies 10D1 and 11.2.1.

[0074] The antibodies 8D2, 8D2(Re), and the 8D2 humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17 can compete with B7 for binding to the antigen CTLA4. Among them, 8D2, 8D2(Re), 8D2H1L1, and 8D2H2L2 are stronger than 10D1 in competing with B7-2 for binding to CTLA4; and 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17 are all stronger than the antibodies 10D1 and 11.2.1 in competing with B7-1 and B7-2 for binding to CTLA4.

[0075] The monoclonal antibody 8D2 and its humanized antibodies of the present invention can block the binding of CTLA4 to B7, specifically relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes very effectively. Among them, 8D2H2L2 and 8D2H2L15 are stronger than the control antibodies 10D1 and 11.2.1 in activating T lymphocytes.

Brief Description of the Drawings

[0076]

Figure 1. Results of SDS-PAGE of the CTLA4ECD-mFc fusion protein. The samples and their loading amounts in the 4 lanes, from left to right, were: M, Marker, 10 μ L; CTLA4ECD-mFc fusion protein, 1 μ g; CTLA4ECD-mFc fusion protein, 2 μ g; CTLA4ECD-mFc fusion protein, 3 μ g.

Figure 2. Results of SDS-PAGE of the 8D2 antibody. The samples and their loading amounts in the 4 lanes, from left to right, were: M, marker, 10 μ L; an antibody sample in the reductive loading buffer for protein electrophoresis, 0.3 μ g; the non-reductive loading buffer for protein electrophoresis, 2 μ L; an antibody sample in the non-reductive loading buffer for protein electrophoresis, 0.3 μ g.

Figure 3. Results of SDS-PAGE of the 8D2 recombinant antibody (8D2(Re)). The samples and their loading amounts in the 4 lanes, from left to right, were: M, marker, 10 μ L; an antibody sample in the reductive loading buffer for protein electrophoresis, 1 μ g; the non-reductive loading buffer for protein electrophoresis, 2 μ L; an antibody sample in the non-reductive loading buffer for protein electrophoresis, 1 μ g.

Figure 4. Results of SDS-PAGE of the humanized antibody of 8D2, 8D2H1L1. The samples and their loading amounts in the 4 lanes, from left to right, were: M, marker, 10 μ L; an antibody sample in the reductive loading buffer for protein electrophoresis, 1 μ g; the non-reductive loading buffer for protein electrophoresis, 2 μ L; an antibody sample in the non-reductive loading buffer for protein electrophoresis, 1 μ g.

Figure 5. Results of SDS-PAGE of the humanized antibody of 8D2, 8D2H2L2. The samples and their loading amounts in the 4 lanes, from left to right, were: M, marker, 10 μ L; an antibody sample in the reductive loading buffer for protein electrophoresis, 1 μ g; the non-reductive loading buffer for protein electrophoresis, 2 μ L; an antibody sample in the non-reductive loading buffer for protein electrophoresis, 1 μ g.

Figure 6. Results of SDS-PAGE of the humanized antibody of 8D2, 8D2H3L3. The samples and their loading amounts in the 4 lanes, from left to right, were: M, marker, 10 μ L; an antibody sample in the reductive loading buffer for protein electrophoresis, 1 μ g; the non-reductive loading buffer for protein electrophoresis, 2 μ L; an antibody sample in the non-reductive loading buffer for protein electrophoresis, 1 μ g.

Figure 7. Results of SDS-PAGE of the humanized antibody of 8D2, 8D2H2L15. The samples

and their loading amounts were: M, marker, 10 μ L; an antibody sample in the non-reductive loading buffer for protein electrophoresis, 1 μ g; an antibody sample in the reductive loading buffer for protein electrophoresis, 1 μ g.

Figure 8. Results of SDS-PAGE of the humanized antibody of 8D2, 8D2H2L17. The samples and their loading amounts were: M, marker, 10 μ L; an antibody sample in the non-reductive loading buffer for protein electrophoresis, 1 μ g; an antibody sample in the reductive loading buffer for protein electrophoresis, 1 μ g.

Figure 9. Results of determining the dynamic characteristic parameters of the mAb 8D2.

Figure 10. Results of determining the dynamic characteristic parameters of 8D2H1L1.

Figure 11. Results of determining the dynamic characteristic parameters of 8D2H2L2.

Figure 12. Results of determining the dynamic characteristic parameters of 8D2H3L3.

Figure 13. Results of determining the dynamic characteristic parameters of 8D2H2L15.

Figure 14. Results of determining the dynamic characteristic parameters of 8D2H2L17.

Figure 15. A histogram showing the expression of CTLA4 on non-labeled 293F cells, isotype control, and 293F-CTLA4 cells as detected using a flow cytometry (cell number - fluorescence (FITC)).

Figure 16. Mean fluorescence intensity (MFI) of the expression of CTLA4 on non-labeled 293F cells, isotype control, and 293F-CTLA4 cells as detected using a flow cytometry.

Figure 17. The EC₅₀ results of the binding of the mAb 8D2 to the labeled 293F-CTLA4 cells.

Figure 18. The EC₅₀ results of the binding of the 8D2(Re) antibody to the labeled 293F-CTLA4 cells.

Figure 19. The EC₅₀ results of the binding of 8D2H1L1 to the labeled 293F-CTLA4 cells.

Figure 20. The EC₅₀ results of the binding of 8D2H2L2 to the labeled 293F-CTLA4 cells.

Figure 21. The EC₅₀ results of the binding of 8D2H3L3 to the labeled 293F-CTLA4 cells.

Figure 22. Determination of the binding of the antibodies 8D2, 8D2H1L1 and 8D2(Re) to CTLA4 using the ELISA method.

Figure 23. Determination of the binding of the recombinant antibodies 8D2H2L2 and 8D2H3L3 to human CTLA4 using the ELISA method.

Figure 24. Determination of the binding of the recombinant antibodies 8D2H2L2 and 8D2H3L3 to monkey CTLA4 using the ELISA method.

Figure 25. Determination of the binding of the recombinant antibodies 8D2H2L15 and

8D2H2L17 to monkey CTLA4 using the ELISA method.

Figure 26. Results of ELISA for competition of the antibodies 8D2, 8D2H1L1 and 8D2(Re) with B7-1.

Figure 27. Results of ELISA for competition of the antibodies 8D2, 8D2H1L1 and 8D2(Re) with B7-2.

Figure 28. Results of ELISA for competition of the 8D2H2L2 and 8D2H3L3 antibodies with B7-1.

Figure 29. Results of ELISA for competition of the 8D2H2L2 and 8D2H3L3 antibodies with B7-2.

Figure 30. Results of ELISA for competition of the 8D2H2L15 and 8D2H2L17 antibodies with B7-1.

Figure 31. Results of ELISA for competition of the 8D2H2L15 and 8D2H2L17 antibodies with B7-2.

Figure 32. Effects on the level of IL-2 secretion by the T lymphocytes as detected by the ELISA method after co-culture of 72 hours with peripheral blood mononuclear cells (PBMC), Raji cells and the humanized antibodies 8D2H1L1, 8D2H2L2 or 8D2H3L3, respectively. The results show that the humanized antibodies of the mAb 8D2 increased the IL-2 secretion by the T lymphocytes by preventing the receptor of CTLA4.

Figure 33. Effects on the level of IL-2 secretion by the T lymphocytes as detected by the ELISA method after co-culture of 72 hours with peripheral blood mononuclear cells (PBMC), Raji cells and the humanized antibodies 8D2H2L15 or 8D2H2L17, respectively. The results show that the humanized antibodies of the mAb 8D2 increased the IL-2 secretion by the T lymphocytes by preventing the receptor of CTLA4.

Figure 34. The growth curve of the tumor subcutaneously transplanted in the hu-SCID-raji model treated with 8D2H2L2.

Specific embodiments

[0077] The embodiments of the invention will be described below in details with reference to the Examples. Those skilled in the art will understand that the following Examples are provided to illustrate the invention. Examples, for which specific techniques or conditions are not described, were performed using the techniques or conditions disclosed in the literatures of the art (e.g., written by J. Sambrook et al., translated by Peitang HUANG et al., Molecular Cloning: A Laboratory Manual, Third Edition, Science Press) or following the instructions provided with the products. Reagents and instruments, for which the supplier is not indicated, are

conventional products which are commercially available.

[0078] In the following Examples of the invention, the BALB/C mice were purchased from Guangdong Medical Laboratory Animal Center.

[0079] In the following Examples of the invention, the T cells used were obtained from Akeso Biopharma Inc., Zhongshan.

[0080] The control antibody, 10D1, was prepared according to US Patent No. 6984720 B1; and 11.2.1 according to US 6682736 B1.

Example. Generation of the CTLA4-8D2 hybridoma cell line LT001 and preparation of the monoclonal antibody 8D2

[0081] Recombinant CTLA4 was expressed in a mammalian cell expression system for immunizing mice as antigen, and hybridoma cells were obtained by fusing mouse spleen cells with myeloma cells. A hybridoma cell line (the CTLA4-8D2 hybridoma cell line LT001) was obtained after screening a great number of samples. Said cell line could secrete the monoclonal antibody 8D2, which specifically binds CTLA4. The specific methods are described below.

1. Synthesis of the CTLA4ECD-mFc gene

[0082] According to the design (SEQ ID NO: 3), the amino acid sequence (SEQ ID NO: 2) corresponding to the extracellular fragment of the CTLA4 gene (Cytotoxic T-Lymphocyte Antigen 4, NCBI Gene ID: 1493, SEQ ID NO: 1) (CTLA4ECD) was fused to the Fc protein fragment of mouse IgG (mFc), wherein mFc refers to the Fc protein fragment of mouse IgG with the amino acid sequence as shown by the underlined part of SEQ ID NO: 3.

[0083] In order to increase the expression efficiency of the gene of interest in the 293f cell expression system, the nucleic acid sequence encoding the SEQ ID NO: 3 protein sequence was optimized at Genscript Co., mainly taking the factors such as codon preference, GC content, secondary structures of mRNA, and repeated sequences into consideration. The final optimized gene encoding the CTLA4ECD-mFc fusion protein has the following sequence (SEQ ID NO: 4), and was synthesized at Genscript Co..

[0084] The sequence of the CTLA4ECD gene (375 bp):

**GCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAG
CCGAGGCATCGCCAGCTTTGTGTGTGAGTATGCATCTCCAGGCA
AAGCCACTGAGGTCCGGGTGACAGTGCTTCGGCAGGCTGACAG
CCAGGTGACTGAAGTCTGTGCGGCAACCTACATGATGGGGAAT
GAGTTGACCTTCCTAGATGATTCCATCTGCACGGGGCACCTCCAG**

 TGGAAATCAAGTGAACCTCACTATCCAAGGACTGAGGGCCATGG
 ACACGGGACTCTACATCTGCAAGGTGGAGCTCATGTACCCACCG
 CCATACTACCTGGGCATAGGCAACGGAACCCAGATTTATGTAAT
 TGATCCAGAACCGTGCCCAGATTCTGAC (SEQ ID NO: 1)

[0085] The sequence of the protein encoded by CTLA4ECD (125 aa):

AMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADS
QVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDT
GLYICKVELMYPPPYLGLGNGTQIYVIDPEPCPDSD (SEQ ID NO:
 2)

[0086] The sequence of the CTLA4ECD-mFc fusion protein (364 aa):

wherein the CTLA4ECD portion is underlined with a waving line, and the mFc portion is underlined with a solid line.

AMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADS
QVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDT
GLYICKVELMYPPPYLGLGNGTQIYVIDPEPCPDSDENLYFQGPRG
PTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMSLSPIVTCVVVDVS
EDDPDVQISWFEVNNVEVHTAQQTQTHREDYNSTLRVVSALPIQHOD
WMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEM
TKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGS
YFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK
 (SEQ ID NO: 3)

[0087] The coding sequence of the gene corresponding to the CTLA4ECD-mFc fusion protein (1092 bp):

wherein the CTLA4ECD portion is underlined with a waving line, and the mFc portion is underlined with a solid line.

GCAATGCATGTGCGCACAGCCTGCAGTGGTCCTGGCAAGCTC
CAGGGGAATCGCTAGCTTCGTGTGCGAATACGCTTCCCCAGGCA
AGGCAACCGAGGTCCGGGTGACAGTCCTGAGACAGGCCGACAG
CCAGGTGACAGAAGTCTGCGCCGCTACTTATATGATGGGCAACG
AGCTGACCTTTCTGGACGATAGCATTTGTACCGGGACATCTAGT
GGAAACCAAGTGAATCTGACCATCCAGGGCCTGCGCGCTATGG
ACACAGCGCTGTACATTTCTAAAGTCCAGCTCATCTATCCCCCT

CCATACTATCTGGGAATCGGCAACGGGACCCAGATCTACGTGAT
TGATCCTGAACCATGCCCCGACTCCGATGAGAATCTGTATTTCC
AGGGACCACGAGGCCCCACAATTAAGCCATGTCCCCCTTGCAAA
TGTCCTGCACCAAACCTGCTGGGAGGACCAAGCGTGTTTCATCTT
TCCACCCAAGATCAAGGACGTGCTGATGATCTCACTGAGCCCCA
TTGTGACCTGCGTGGTTCGTGGACGTGAGCGAGGACGATCCTGA
TGTGCAGATCAGTTGGTTCGTCAACAATGTGGAAGTCCACACAG
CTCAGACTCAGACCCATAGGGAGGATTACAATAGTACTCTGCGC
GTCGTGTCAGCACTGCCCCATTCAGCACCAGGACTGGATGAGCG
GCAAGGAGTTCAAGTGCAAAGTGAACAACAAGGATCTGCCCGC
ACCTATCGAGAGAACTATTTCCAAGCCTAAAGGGTCTGTGAGGG
CCCCACAGGTGTATGTCCTGCCTCCACCCGAGGAAGAGATGACT
AAGAAACAGGTGACACTGACTTGTATGGTCCACCGACTTCATGCC
CGAAGATATCTACGTGGAGTGGACTAACAATGGGAAGACCGAA
CTGAACTATAAAAATACAGAGCCTGTGCTGGACTCAGATGGAAG
CTACTTTATGTATAGCAAGCTGCGAGTGGAAAAGAAAAACTGGG
TCGAGCGGAACAGCTACTCTTGTAGTGTGGTCCACGAAGGGCTG
CATAATCACCACACCACTAAATCATTCTCCCGAACTCCAGGCAA
A (SEQ ID NO: 4)

2. Generation of the pUC57simple-CTLA4ECD-mFc plasmid

[0088] The synthesized CTLA4ECD-mFc fusion gene (SEQ ID NO: 4) was cloned into the pUC57simple expression vector (provided by Genscript Co.) at Genscript Co., resulting in the pUC57simple-CTLA4ECD-mFc plasmid.

3. Construction of the pcDNA3.1-CTLA4ECD-mFc recombinant plasmid

[0089] The pUC57simple-CTLA4ECD-mFc plasmid was digested with the endonucleases Xba I and BamH I. The CTLA4ECD-mFc fusion gene fragment was recovered via electrophoresis and was ligated into the pcDNA3.1 expression vector (purchased from Invitrogen Co.). The resultant pcDNA3.1-CTLA4ECD-mFc plasmid was used to transfect the competent cells of the DH5a strain of *E. coli* (purchased from TIANGEN Co.). Transfection and culture were performed following the instructions. *E. coli* colonies positive for pcDNA3.1-CTLA4ECD-mFc

were screened out and propagated following conventional methods. Then, the pcDNA3.1-CTLA4ECD-mFc recombinant plasmid was extracted using a kit (purchased from Tiangen Biotech (Beijing) Co. LTD, DP103-03) following the instructions provided with the kit.

[0090] 4. Cells of 293F (purchased from Invitrogen Co.) were transfected with the pcDNA3.1-CTLA4ECD-mFc recombinant plasmid using the lipofectamin transfection kit (purchased from Invitrogen Co.).

[0091] 5. Seven days after transfecting 293F cells with the pcDNA3.1-CTLA4ECD-mFc recombinant plasmid, the CTLA4ECD-mFc fusion protein was purified from the culture liquid by high speed centrifugation, vacuum filtration through a microporous filter membrane, and HiTrap protein A HP column chromatography. After purification, samples were taken, added into the reductive loading buffer for protein electrophoresis, and examined by SDS-PAGE electrophoresis. As shown in Figure 1, the protein of interest is shown as a band at about 45 kD.

6. Generation of the CTLA4-8D2 hybridoma cell line LT001

[0092] Using the CTLA4ECD-mFc fusion protein as the antigen, hybridoma cells were obtained by fusing the splenic cells from the immunized BALB/C mice (purchased from Guangdong Medical Laboratory Animal Center) with mouse myeloma cells following an established method (e.g., Stewart, S. J., "Monoclonal Antibody Production", in Basic Methods in antibody Production and Characterization, Eds. G. C. Howard and D. R. Bethell, Boca Raton: CRC Press, 2000).

[0093] CTLA4 was used as the antigen to coat an ELISA plate, and hybridoma cells secreting novel antibodies specifically binding to CTLA4 were obtained by an indirect ELISA screening. Hybridoma cell lines secreting monoclonal antibodies which competed with the ligand B7-1 (CD80, NCBI Gene ID: 941) or B7-2 (CD86, NCBI Gene ID: 942) for binding to CTLA4 were obtained by a competitive ELISA screening from the hybridoma cells obtained in the indirect ELISA screening. A stable hybridoma cell line was obtained via limited dilution. The hybridoma cell line was designated as the CTLA4-8D2 hybridoma cell line, and the CTLA4-8D2 stable cell line was obtained via limited dilution (also referred to as LT001 in the present invention; the monoclonal antibody secreted by it was designated as 8D2).

7. Preparation of the antibody 8G2

[0094] The CTLA4-8D2 (LT001) cell line of the present invention was cultured in a medium supplemented with 10% fetal bovine serum with low IgG. Seven days later, the supernatant of the cell culture was collected to purify the antibody 8D2.

8. Detection of the 8D2 antibody by SDS-PAGE

[0095] Purified samples were added into the reductive loading buffer for protein electrophoresis and the non-reductive loading buffer for protein electrophoresis. After boiling, detection was performed. The results show that the protein of interest is shown as two band at about 50 kD and 25 kD for the reductive protein sample, or as a band at about 150 kD for the non-reductive protein sample (Figure 2).

Example 2. Determination of the light chain and heavy chain sequences of the monoclonal antibody 8D2

[0096] Following the instructions of the Cultured Cell/Bacteria Total RNA Extraction Kit (Tiangen, Cat. No. DP430), mRNA was extracted from the CTLA4-8D2 hybridoma cell line (LT001 cell) generated in Example 1.

[0097] Following the instructions of the Invitrogen SuperScript® III First-Strand Synthesis System for RT-PCR kit, cDNA was synthesized and amplified by PCR. The PCR amplication product was immediately subjected to TA cloning, following the instructions of the pEASY-T1 Cloning Kit (TransGen, Cat. No. CT101). The product of TA cloning was immediately subjected to sequenceing, and the sequencing results are provided below.

[0098] The results of DNA sequencing of the heavy chain variable region (345 bp):

**GAGGTGAAACTGGACGAACTGGCGGGGGGCTGGTGACAGC
CCGGACGACCTATGAAGCTGTCATGCGTCGCCAGCGGCTTCACC
TTAGCGACAACCTGGATGAATTGGGTGAGGCAGAGCCCAGAGA
AGGGGCTGGAATGGCTGGCTCAGATCCGCAACAAACCCTACAAT
TATGAGACCTACTATTCTGACAGTGTGAAGGGCCGGTTCACAAT
TTCCAGAGACGATTCTAAAAGCTCCGTCTACCTGCAGATGAACA
ATCTGAGAGGCGAAGATATGGGGATCTACTATTGCACAGCACAG
TTCGCTTATTGGGGACAGGGCACTCTGGTCACAGTCTCCGCC
(SEQ ID NO: 5)**

[0099] The protein sequence encoded by it (115 aa):

**EVKLDETGGGLVQPGRPMKLSCVASGFTFSDNWMNWVRQSP
EKGLEWLAQIRNKPYNYETYYSDSVKGRFTISRDDSKSSVYLQMNN
LRGEDMGIYYCTAQFAYWGQGLVTVSA (SEQ ID NO: 6)**

[0100] The results of DNA sequencing of the light chain variable region (318 bp):

**GACATTCAGATGACACAGAGTCCTGCTTCCCTGAGTGCCTC
AGTGGGGGAGACCGTCACAATCACTTGCGGCACCTCTGAAAACA
TCTACGGCGGGCTGAATTGGTATCAGCGGAAGCAGGGCAAAAG
TCCCCAGCTGCTGATCTTCGGAGCAACAAACCTGGCCGACGGCA
TGAGCTCCCGGTTTAGCGGGTCCGGATCTGGCAGACAGTACAG
CCTGAAGATTTCTAGTCTGCACCCAGACGATGTGGCTACTTACT
ATTGCCAGAATGTCCTGAGGAGTCCCTTCACCTTTGGGGTCAGGA
ACAAAGCTGGAGATC (SEQ ID NO: 7)**

[0101] The protein sequence encoded by it (106 aa):

**DIQMTQSPASLSASVGETVTITCGTSENIYGGLNWKYQKQGKS
PQLLIFGATNLADGMSSRFSGSGSGRQYSLKISLHPDDVATYYCQN
VLRSPFTFGSGTKLEI (SEQ ID NO: 8)**

Example 3. Design of the light chain and heavy chain sequences of the humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15 and 8D2H2L17

[0102] Based on the three-dimensional crystal structure of the CTLA4 protein (Nat. Struct. Biol. (1997) 4, p. 527) and the sequences of the 8D2 antibody obtained in Example 2, the structure of the antibody was modeled on computer. The variable region sequences of the antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15 and 8D2H2L17 were designed based on the antibody sequences and the structural model (the constant region sequences of the antibodies were from the NCBI database). The variable region sequences are provided below.

1. The light chain and heavy chain sequences of the monoclonal antibody 8D2H1L1

[0103] The DNA sequence of the heavy chain variable region (345 bp):

**GAAGTGCAGCTGGTCGAGTCCGGGGGGGGCCTGGTGCAGC
CAGGAGGATCAATGCGACTGAGCTGCGCCGCTTCCGGCTTCACC
TTCAGCGACAACCTGGATGAATTGGGTCAGGCAGGCACCAGGAA
AGGGACTGGAGTGGCTGGCACAGATCCGCAACAAACCTTACAA
CTACGAAACTTACTACAGCGACTCCGTGAAGGGGGCGGTTCACCA
TTTCTAGAGACGATTCTAAAAACAGTGTGTACCTGCAGATGAAT
AGCCTGAAGACCGAGGATACAGGAGTCTACTATTGTACCGCACA**

GTTTGCTTATTGGGGGCAGGGCACTCTGGTGACAGTCTCTTCA
(SEQ ID NO: 9)

[0104] The protein sequence encoded by it (115 aa):

EVQLVESGGGLVQPGGSMRLSCAASGFTFSDNWMNWVRQAP
GKGLEWLAQIRNKPYNYETYYSVSKGRFTISRDDSKNSVYLQMNS
LKTEDTGVYYCTAQFAYWGQGTLVTVSS (SEQ ID NO: 10)

[0105] The DNA sequence of the light chain variable region (321 bp):

GACATTCAGATGACTCAGAGCCCTTCAAGCCTGTCCGCATC
TGTGGGCGACCGAGTCACCATCACATGCAGAACCTCCGAGAACA
TCTACGGCGGGCTGAATTGGTATCAGCGAAAGCAGGGGAAAAG
TCCCAAGCTGCTGATCTACGGGGCAACAAACCTGGCCAGCGGA
ATGAGCTCCAGATTCAGTGGATCAGGCAGCGGGACAGATTATAC
TCTGAAAATTTCTAGTCTGCACCCAGACGATGTGGCAACCTACT
ATTGCCAGAATGTCCTGAGGTCACCCTTCACCTTTGGAAGCGGC
ACAAAACCTGGAGATCAAG (SEQ ID NO: 11)

[0106] The protein sequence encoded by it (107 aa):

DIQMTQSPSSLSASVGDRVTITCRTSENIYGGLNWDYQQRKQGKS
PKLLIYGATNLAAGMSSRFSGSGSGTDYTLKISSLHPDDVATYYCQN
VLRSPFTFGSGTKLEIK (SEQ ID NO: 12)

2. The light chain and heavy chain sequences of the 8D2 humanized monoclonal antibody 8D2H2L2

[0107] The DNA sequence of the heavy chain variable region (345 bp):

GAAGTGCAGCTGGTCGAGTCCGGGGGGGGCCTGGTGCAGC
CAGGAGGATCAATGCGACTGAGCTGCGCCGCTTCCGGCTTCACC
TTCAGCGACAACCTGGATGAATTGGGTCAGGCAGGCACCAGGAA
AGGGACTGGAGTGGCTGGCACAGATCCGCAACAAACCTTACAA
CTACGAAACTTACTACAGCGCCTCCGTGAAGGGGGCGGTTCACCA
TTTCTAGAGACGATTCTAAAAACAGTGTGTACCTGCAGATGAAT
ACCGCTCAACAGCCGACCATACAGCACTCTACTATTCTACCCGACA

**AGCCTGAAGACCGAGGATACAGGAGTCTACTATTGTACCGCACA
GTTTGCTTATTGGGGGCAGGGCACTCTGGTGACAGTCTCTTCA
(SEQ ID NO: 13)**

[0108] The protein sequence encoded by it (115 aa):

**EVQLVESGGGLVQPGGSMRLSCAASGFTFSDNWMNWVRQAP
GKGLEWLAQIRNKPYNYETYYSASVKGRFTISRDDSKNSVYLQMNS
LKTEDTGVYYCTAQFAYWGQGTLVTVSS (SEQ ID NO: 14)**

[0109] The DNA sequence of the light chain variable region (321 bp):

**GACATTCAGATGACTCAGAGCCCTTCAAGCCTGAGTGCCTC
AGTGGGAGACCGGGTCACCATCACATGCAGAACCAGCGAGAAC
ATCTACGGCGGCCTGAACTGGTATCAGCGAAAGCCAGGCAAGA
GCCCCAAGCTGCTGATCTACGGGGCAACCAACCTGGCCTCTGGA
GTGAGCTCCAGATTCAGCGGCAGCGGCTCTGGGACCGACTATA
CTCTGACCATTTCTAGTCTGCAGCCTGAAGATGTGGCAACATAC
TATTGCCAGAATGTCCTGAGGTCCCCATTACCTTTGGATCTGG
CACCAAGCTGGAGATCAAG (SEQ ID NO: 15)**

[0110] The protein sequence encoded by it (107 aa):

**DIQMTQSPSSLSASVGDRVTITCRTSENIYGGLNWDYQRPKSP
KLLIYGATNLSGVSSRFSGSGSGTDYTLTISSLQPEDVATYYCQNV
LRSPFTFGSGTKLEIK (SEQ ID NO: 16)**

3. The light chain and heavy chain sequences of the 8D2 humanized monoclonal antibody 8D2H3L3

[0111] The DNA sequence of the heavy chain variable region (345 bp):

**GAGGTGCAGCTGGTTCGAGTCTGGAGGCGGCCTGGTGCAGC
CCGGCGGGTCACTGCGACTGAGCTGCGCCGCTTCCGGCTTCAC
CTTCAGCGACAACCTGGATGAATTGGGTGAGGCAGGCACCCGGG
AAGGGGCTGGAGTGGGTTCGCTCAGATCCGCAACAAACCTTACA
ATTATGAGACAGAATACGCAGCCTCTGTGAAGGGGCGGTTCACT
ATTAGTAGAGACGATAGCAAGAACAGCGCCTATCTGCAGATGAA**

**TAGCCTGAAGACCGAAGATACAGCCGTCTACTATTGTACAGCTC
AGTTTGCATACTGGGGCCAGGGAACTCTGGTGACCGTCAGCTCC
(SEQ ID NO: 17)**

[0112] The protein sequence encoded by it (115 aa):

**EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNWMNWVRQAPG
KGLEWVAQIRNKPYNYTEYAASVKGRFTISRDDSKNSAYLQMNSL
KTEDTAVYYCTAQFAYWGQGTLVTVSS (SEQ ID NO: 18)**

[0113] The DNA sequence of the light chain variable region (321 bp):

**GACATTCAGATGACTCAGAGCCCTTCTTCTCTGTCCGCATCT
GTGGGAGACCGGGTCACCATCACATGCAGAGCCAGCGAGAACA
TCTACGGCGGCCTGAACTGGTATCAGCAGAAGCCAGGCAAAGC
TCCCAAGCTGCTGATCTACGGAGCAACCTCCCTGGCATCTGGAG
TGCCATCCCGGTTTCAGTGGATCAGGCAGCGGGACCGACTATACT
CTGACCATTAGCTCCCTGCAGCCTGAAGACTTCGCCACATACTA
TTGCCAGAACGTGCTGAGGTCCCCATTACCTTTGGATCTGGCA
CCAAGCTGGAGATCAAG (SEQ ID NO: 19)**

[0114] The protein sequence encoded by it (107 aa):

**DIQMTQSPSSLSASVGDRVTITCRASENIYGGLNWDYQKPGKA
PKLLIYGATSLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQNV
LRSPFTFGSGTKLEIK (SEQ ID NO: 20)**

4. The light chain and heavy chain sequences of the 8D2 humanized monoclonal antibody 8D2H2L15

[0115] The DNA sequence of the heavy chain variable region (345 bp):

**GAAGTGCAGCTGGTCGAGTCCGGGGGGGGCCTGGTGC
AGCCAGGAGGATCAATGCGACTGAGCTGCGCCGCTTCCGG
CTTCACCTTCAGCGACAACCTGGATGAATTGGGTCAGGCAGG
CACCAGGAAAGGGACTGGAGTGGCTGGCACAGATCCGCAA
CAAACCTTACAACCTACGAAACTTACTACAGCGCCTCCGTGA**

**AGGGGCGGTTCACCATTTCTAGAGACGATTCTAAAAACAGT
GTGTACCTGCAGATGAATAGCCTGAAGACCGAGGATACAGG
AGTCTACTATTGTACCGCACAGTTTGCTTATTGGGGGCAGG
GCACTCTGGTGACAGTCTCTTCA (SEQ ID NO: 13)**

[0116] The protein sequence encoded by it (115 aa):

**EVQLVESGGGLVQPGGSMRLSCAASGFTFSDNWMNWVR
QAPGKGLEWLAQIRNKPYNYETYYSASVKGRFTISRDDSKNSV
YLQMNSLKTEDTGVYYCTAQFAYWGQGTLVTVSS (SEQ ID
NO: 14)**

[0117] The DNA sequence of the light chain variable region (321 bp):

**GACATCCAGATGACTCAGTCTCCCAGCTCCCTGTCCGC
TTCTGTGGGCGATCGGGTCACTATCACCTGTAGAACCAGCG
AGAACATTTACGGCGGACTGAATTGGTATCAGAGGAAGCCC
GGGAAAAGTCCTAAGCTGCTGATCTACGGAGCAACAAACCT
GGCCTCCGGCGTGTCTAGTCGCTTCAGTGGATCAGGCAGCG
GGACCGACTATACACTGACTATTTCAAGCCTGCAGCCAGAG
GATGTGGCCACATACTATTGCCAGAATGTCCTGAGCCGGCA
CCCCGGATTTGGCTCAGGGACCAAACTGGAAATTAAG (SEQ
ID NO: 21)**

[0118] The protein sequence encoded by it (107 aa):

**DIQMTQSPSSLSASVGDRVTITCRTSENIYGGLNWFYQRKP
GKSPKLLIYGATNLASGVSSRFSGSGSGTDYTLTISSLQPEDVAT
YYCQNVLSRHPGFGSGTKLEIK (SEQ ID NO: 22)**

5. The light chain and heavy chain sequences of the 8D2 humanized monoclonal antibody 8D2H2L17

[0119] The DNA sequence of the heavy chain variable region (345 bp):

**GAAGTGCAGCTGGTCGAGTCCGGGGGGGGCCTGGTGC
AGCCAGGAGGATCAATGCGACTGAGCTGCGCCGCTTCCGG
CTTCACCTTCAGCGACAACTGGATGAATTGGGTCAGGCAGG**

CACCAGGAAAGGGACTGGAGTGGCTGGCACAGATCCGCAA
 CAAACCTTACAACACTACGAACTTACTACAGCGCCTCCGTGA
 AGGGGCGGTTCACCATTCTAGAGACGATTCTAAAAACAGT
 GTGTACCTGCAGATGAATAGCCTGAAGACCGAGGATACAGG
 AGTCTACTATTGTACCGCACAGTTTGCTTATTGGGGGCAGG
 GCACTCTGGTGACAGTCTCTTCA (SEQ ID NO: 13)

[0120] The protein sequence encoded by it (115 aa):

EVQLVESGGGLVQPGGSMRLSCAASGFTFSDNWMNWVR
 QAPGKGLEWLAQIRNKPYN YETYY SASVKGRFTISRDDSKNSV
 YLQMNSLKTEDTGVYYCTAQFAYWGQGTLVTVSS (SEQ ID
 NO: 14)

[0121] The DNA sequence of the light chain variable region (321 bp):

GACATCCAGATGACTCAGTCACCCAGCTCCCTGAGTG
 CTTCAAGTGGGCGATCGGGTCACTATCACCTGTAGAACCAGC
 GAGAACATTTACGGCGGACTGAATTGGTATCAGAGGAAGCC
 CGGGAAAAGCCCTAAGCTGCTGATCTACGGAGCAACAAACC
 TGGCCTCCGGCGTGTCTAGTCGCTTCAGCGGCAGCGGCTCT
 GGAACCGACTATACTGACTATTTCAAGCCTGCAGCCAGA
 GGATGTGGCCACATACTATTGCCAGAATGTCCTGTCCTCTC
 GACCCGGATTTGGCAGTGGGACCAAACCTGGAAATTAAG
 (SEQ ID NO: 23)

[0122] The protein sequence encoded by it (107 aa):

DIQMTQSPSSLSASVGDRVITTCRTSENIYGGLNWKYQRP
 GKSPKLLIYGATNLSGVSSRFSGSGSGTDYTLTISSLQPEDVAT
 YYCQNVLSRPGFGSGTKLEIK (SEQ ID NO: 24)

Example 4. Preparation of the 8D2 recombinant antibody, 8D2(Re), and the 8D2
 humanized antibodies, 8D2H1L1, 8D2H2L3, 8D2H3L3, 8D2H2L15 and 8D2H2L17, and
 detection by SDS-PAGE

1. Preparation of the 8D2 recombinant antibody, 8D2(Re), and detection by SDS-PAGE

[0123] The cDNA sequence of the heavy chain (its variable region sequence is shown in SEQ ID NO: 5) and the cDNA sequence of the light chain (its variable region sequence is shown in SEQ ID NO: 7) of 8D2 were cloned into the pUC57simple vector (provided by Genscript Co.), respectively, resulting in the plasmids pUC57simple-8D2H and pUC57simple-8D2L.

[0124] The plasmids pUC57simple-8D2H and pUC57simple-8D2L were digested with the endonucleases (Hind III and EcoR I), respectively. The fragments encoding the heavy chain and light chain recovered via electrophoresis were separately subcloned into the pcDNA3.1 vector. The recombinant plasmids were extracted and co-transfected into cells of 293F. After 7 days of cell culture, the culture liquid was subjected to high speed centrifugation, vacuum filtration through a microporous filter membrane and purification on a HiTrap Protein A HP column. Purified samples were added into the reductive loading buffer for protein electrophoresis and the non-reductive loading buffer for protein electrophoresis. After boiling, detection was performed by SDS-PAGE. As shown in Figure 3, the protein of interest is shown as two band at about 50 kD and 25 kD for the reductive protein sample, or as a band at about 150 kD for the non-reductive protein sample.

2. Preparation of the 8D2 humanized antibodies, 8D2H1L1, 8D2H2L2 and 8D2H3L3, and detection by SDS-PAGE

[0125] The cDNA sequences of the heavy chain (their variable region sequences are shown in SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 13, SEQ ID NO: 13, respectively) and the cDNA sequences of the light chain (their variable region sequences are shown in SEQ ID NO: 11, SEQ ID NO: 15, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, respectively) of 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17 were cloned into the pUC57simple vector (provided by Genscript Co.), respectively, resulting in the plasmids pUC57simple-8D2H1L1, pUC57simple-8D2H2L2, pUC57simple-8D2H3L3, pUC57simple-8D2H2L15, and pUC57simple-8D2H2L17. They were separately subcloned into the pcDNA3.1 vector following the procedure described above for 8D2(Re).

[0126] The recombinant plasmids were transfected into cells of 293F. The culture liquid of the 293F cells were subjected to detection after purification following the procedure described above for 8D2(Re). The results are shown in Figure 4, Figure 5, Figure 6, Figure 7, and Figure 8. The reductive protein samples showed the proteins of interest as two bands at about 50 kD and 25 kD, and the non-reductive protein samples showed the proteins of interest as a band at about 150 kD.

[0127] The 8D2 recombinant antibody, 8D2(Re), and the 8D2 humanized antibodies, 8D2H1L1, 8D2H2L3, 8D2H3L3, 8D2H2L15 and 8D2H2L17 used in the following examples

were prepared following the procedure described in this example.

Example 5. Determination of the dynamic parameters of the antibodies

[0128] The dynamic parameters of the binding of the antibodies 8D2 and humanized 8D2H1L1, 8D2H2L2 and 8D2H3L3 to the antigen CTLA4 (NCBI Gene ID: 1493, with the coding nucleic acid sequence as shown in SEQ ID NO: 25 and the encoded amino acid sequence as shown in SEQ ID NO: 26) were determined using the Fortebio molecular interaction analyzer.

1. 1. The CTLA4-mFc protein (CTLA4-mFc was generated following the same method as that described in Example 1 for the synthesis of CTLA4ECD-mFc) was cleaved with the TEV protease, and the CTLA4 antigen was obtained by purification on a column.

The sequence of the CTLA4 gene (636 bp):

**ATGGGCGTCCTGCTGACTCAGAGAACCCTGCTGTCCCTGGT
GCTGGCACTGCTGTTTCCTTCAATGGCTTCAATGGCTATGCATG
TGGCTCAGCCAGCAGTGGTCCTGGCAAGCTCCAGGGGGGATCGC
CAGTTTCGTGTGCGAGTACGCCTCACCTGGAAAGGCTACAGAAG
TCCGGGTGACTGTCCTGAGACAGGCTGACTCTCAGGTGACCGA
GGTCTGCGCCGCTACATATATGATGGGCAACGAACCTGACCTTTC
TGGACGATTCCATTTGTACTGGCACCTCTAGTGGGAACCAAGTG
AATCTGACTATCCAGGGACTGCGAGCAATGGACACCGGACTGTA
CATTGCAAAGTGGAGCTGATGTATCCCCCTCCATACTATCTGG
GCATCGGGAATGGAACACAGATCTACGTGATTGATCCCGAACCT
TGTCCAGACAGCGATTTCCTGCTGTGGATTCTGGCAGCCGTGTC
AAGCGGCCTGTTCTTTTATAGCTTTCTGCTGACTGCCGTCTCCCT
GTCTAAGATGCTGAAGAAACGATCCCCCCTGACCACAGGGGTG
GTCGTGAAAATGCCACCTACCGAGCCCGAGTGCGAAAAACAGTT
CCAGCCATACTTTATCCCTATCAAT (SEQ ID NO: 25)**

The encoded corresponding amino acid sequence (212 aa):

**MGVLLTQRTL LSLVLALLFPSMASMAMHVAQPAVVLASSRGI
ASFVCEYASPGKATEVRVTVLRLQADSQVTEVCAATYMMGNELTEL
DDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYLIGIG
NGTQIYVIDPEPCPDSDFLWILAAVSSGLFFYSFLLTAVSLSKMLK
KRSPLTTGVVVKMPPTPECEKQFQPYFIPIN (SEQ ID NO: 26)**

2. 2. The antibody 8D2 and its humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17 were immobilized on the surface of the AR2G sensor by amino coupling, and blocked with ethanolamine. After equilibration in PBST, the CTLA4

antigen was added for binding. CTLA4 was serially 2x diluted in PBST, and the following concentrations were obtained: 300, 150, 75, 37.5, 18.75, 9.38, 4.69, 0 nM. Dissociation occurred in PBST. The humanized antibodies 8D2H1L1, H2L2, H3L3, H2L15, and H2L17 were detected by a method same as 8D2, and the antigen concentrations were 180, 90, 45, 22.5, 11.25, 5.625, 2.813, 0nM.

[0129] The dynamic parameters of the antibody 8D2 and its humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17 are provided in Table 1, and the results of determining the dynamic characteristic parameters are shown in Figures 9 to 14, respectively.

Table 1. Dynamic parameters of the antibodies 8D2, 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17

Antibody Name	K_D (M)	k_{on} (1/Ms)	k_{on} Error	k_{dis} (1/s)	k_{dis} Error
8D2	1.66E-10	1.42E+05	1.22E+03	2.36E-05	2.09E-06
8D2H1L1	6.08E-10	3.40E+05	1.17E+04	2.07E-04	1.81E-05
8D2H2L2	9.55E-10	4.07E+05	1.59E+04	3.88E-04	1.60E-05
8D2H3L3	1.05E-09	3.12E+05	1.01E+04	3.27E-04	1.41E-05
8D2H2L15	1.02E-09	4.54E+05	8.18E+03	4.65E-04	9.50E-06
8D2H2L17	7.66E-10	4.59E+05	8.21E+03	3.52E-04	8.30E-06
10D1	1.21E-09	4.67E+05	1.15E+04	5.65E-04	1.51E-05
11.2.1	9.03E-10	3.87E+05	5.46E+03	3.49E-04	7.32E-06
K_D , affinity constant; k_{on} , antigen - antibody association rate; k_{dis} , antigen - antibody dissociation rate; $K_D=k_{dis}/k_{on}$.					

[0130] The results demonstrate that all of the six antibodies have a good affinity for the antigen, which is comparable or even superior than the control antibodies 10D1 and 11.2.1.

Example 6. Determination of the activity of the antibodies to bind to the antigen CTLA4 on the surface of the hybridoma cell line by flow cytometry

[0131] First, 293F host cells expressing the CTLA4 antigen were generated, and labeled with the monoclonal antibody 8D2 (Example1) and 8D2(Re) and the 8D2 humanized antibodies 8D2H1L1, 8D2H2L2 and 8D2H3L3 (Example 4) prepared in the present invention, respectively. Then, the ability of the antibodies to specifically bind to the antigen having native conformation on the surface of cells was verified by flow cytometry.

[0132] The specific steps are provided below.

1. Generation of 293F host cells expressing the CTLA4 antigen

[0133] Cells of 293F were transfected with the plasmid pLenti6.3-CTLA4 for CTLA4 (the vector pLenti6.3 was purchased from Invitrogen Co.) using the Lipofectamin transfection kit (purchased from Invitrogen Co.). After screening, a clonal population of cells stably expressing CTLA4 (293F-CTLA4) was obtained.

2. Labeling with the antibodies and detection using a flow cytometer

[0134] The 293F host cells expressing the CTLA4 antigen obtained by the above steps were digested with trypsin following a conventional method, and 2×10^5 cells were added to each collection tube. The diluted solutions of the 8D2 antibody in PBS containing 1% BSA were prepared to achieve the concentrations of 20 nM, 10 nM, 5 nM, 1 nM, 0.1 nM, 0.01 nM, and 0 nM, respectively. After incubation with 293F cells expressing CTLA4 on ice for 2 hours, 100 μ L FITC-Goat-Anti-Mouse IgG (1:500) was added to each tube, and the tubes were incubated on ice for 1 hour. After addition of 300 μ L PBS, the fluorescent signal was detected using the FITC channel on the flow cytometer. Other antibodies were detected in a similar way to the 8D2 antibody.

3. Results

[0135] The results of verifying the expression of CTLA4 on 293F-CTLA4 cells are shown in Figure 15 and Figure 16, respectively. The results of the binding of the antibodies 8D2, 8D2(Re), and the three humanized antibodies to 293F cells are shown in Figures 17 to 21, respectively. As shown in the figures, the 8D2 antibody and its humanized antibodies can effectively bind to the CTLA4 target protein on the surface of the 293F host cell, and their binding efficiency is dose-dependent. The fluorescent intensities at each dose are provided in Table 2.

[0136] The binding efficiency, EC_{50} , of 8D2 and its humanized antibodies was obtained by curve simulation in the fluorescent quantitative analysis of the bound antibodies 8D2 and its humanized antibodies, which is shown in Table 3.

Table 2. Fluorescent intensity analysis determining the binding of 8D2, 8D2(Re) and the 8D2 humanized antibodies 8D2H1L1, 8D2H2L2 and 8D2H3L3 to the CTLA4 antigen on the surface of the 293F-CTLA4 host cell by flow cytometry

	8D2	8D2(Re)	8D2H1L1	8D2H2L2	8D2H3L3
concentration (nM)	fluorescence intensity				
0.001	7.60	24.62	10.84	10.85	10.85
0.01	7.70	24.72	10.85	32.48	25.14
0.1	9.10	66.72	21.25	124.03	108.29
1	25.50	321.27	103.04	624.65	623.25
5	182.60	713.87	558.75	972.03	970.80
10	638.60	897.63	943.84	1159.24	1084.74
25	721.80	873.24	1170.64	1132.39	1091.77

Table 3. The binding efficiency, EC_{50} , of 8D2, 8D2(Re) and the 8D2 humanized antibodies 8D2H1L1, 8D2H2L2 and 8D2H3L3 to the CTLA4 antigen on the surface of the 293F-CTLA4 host cell obtained by curve simulation in the analysis by flow cytometry

	8D2	8D2(Re)	8D2H1L1	8D2H2L2	8D2H3L3
EC_{50} (nM)	3.84	1.38	5.06	4.37	4.54

[0137] The results demonstrate that the antibodies 8D2, 8D2(Re) and the 8D2 humanized antibodies 8D2H1L1, 8D2H2L2 and 8D2H3L3 all have a very strong capability to bind to the CTLA4 antigen on the surface of the 293F-CTLA4 host cells.

Example 7. Determination of the activity of the antibodies to bind to the CTLA4 antigen by ELISA

[0138] The ELISA plate was coated with CTLA4 at 4 °C over night. After blocking with 1% BSA at 37 °C for 2 h, the CTLA4 antibodies 8D2, 8D2(Re) and the 8D2 humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17, and the control antibodies 10D1 (Alan J. Korman, Edward L. Halk, et al., HUMAN CTLA-4 ANTIBODIES, United State Patent No. US 6984720 B1) and 11.2.1 (Douglas Charles Hanson, Mark Joseph Neveu, et al., Human monoclonal antibodies to CTLA-4, United State Patent No. US 682736 B1) were added for reaction for 30 min. The enzyme conjugated secondary antibody was added for incubation for 30 min. Then, the absorbance at 450 nm was determined on an ELISA plate reader.

[0139] The results of detecting the binding of the 8D2 antibody and its humanized antibodies to the CTLA4 antigen are shown in Figures 22 to 25, respectively. As shown in the figures, the antibodies 8D2, 8D2(Re) and the 8D2 humanized antibodies all can effectively bind to the CTLA4 protein, and their binding efficiency is dose-dependent. The fluorescent intensities at each dose are provided in Tables 4 to 8. The binding efficiency, EC_{50} , of 8D2, 8D2(Re) and the humanized antibodies was obtained by curve simulation in the fluorescent quantitative analysis of the bound 8D2, 8D2(Re) and the humanized antibodies (Table 9).

Talbe 4. Binding of 8D2 and 8D2(Re) to murine CTLA4 (ELISA)

Antibody concentration ($\mu\text{g/ml}$)	Antigen coating: murine CTLA4 at 0.5 $\mu\text{g/ml}$					
	8D2		8D2(Re)		10D1	
1	2.823	2.682	2.672	2.769	2.995	2.975
0.3	2.806	2.763	2.690	2.735	2.852	2.900
0.1	2.754	2.718	2.796	2.685	2.429	2.538
0.03	2.336	2.381	2.305	2.259	1.507	1.704
0.01	1.614	1.560	1.397	1.446	0.673	0.794
0.003	0.784	0.760	0.662	0.674	0.292	0.328
0.001	0.358	0.355	0.315	0.321	0.136	0.142
0	0.063	0.052	0.053	0.046	0.046	0.050
Secondary antibody	Goat Anti Mouse Secondary Antibody				Goat Anti Human Secondary Antibody	

Talbe 5. Binding of 8D2, 8D2H1L1 and 8D2(Re) to human CTLA4 (ELISA)

Antibody concentration ($\mu\text{g/ml}$)	Antigen coating: human CTLA4 at 0.5 $\mu\text{g/ml}$									
	10D1		11.2.1		8D2H1L1		8D2		8D2(Re)	
1	3.479	3.432	3.584	3.547	3.016	3.031	3.029	3.107	3.058	3.085
1:3	3.323	3.155	3.499	3.479	2.834	2.904	3.076	3.074	2.930	3.072
1:9	2.506	2.293	3.211	3.187	2.610	2.670	2.878	2.988	2.805	2.868
1:27	1.331	1.194	2.337	2.293	1.834	1.944	2.265	2.287	2.052	2.064
1:81	0.552	0.528	1.254	1.267	0.969	0.996	1.335	1.479	1.398	1.271
1:243	0.202	0.222	0.536	0.552	0.450	0.515	0.666	0.770	0.634	0.649
1:729	0.141	0.115	0.253	0.263	0.204	0.206	0.277	0.351	0.307	0.309
0	0.090	0.086	0.072	0.064	0.067	0.067	0.064	0.067	0.071	0.086
Secondary antibody	Goat Anti Human IgG Secondary Antibody						Goat Anti Mouse IgG Secondary Antibody			

Talbe 6. Binding of 8D2H2L2 and 8D2H3L3 to human CTLA4 (ELISA)

Antibody concentration ($\mu\text{g/ml}$)	Antigen coating: human CTLA4 at 0.5 $\mu\text{g/ml}$							
	8D2H2L2		8D2H3L3		10D1		11.2.1	
1	1.489	1.411	1.631	1.601	1.775	2.069	2.206	2.150
1:3	1.178	1.262	1.192	1.455	1.527	1.480	1.825	2.047
1:9	0.710	0.872	0.943	1.007	1.073	1.204	1.292	1.409
1:27	0.336	0.370	0.642	0.658	0.663	0.585	0.893	0.682
1:81	0.192	0.195	0.415	0.374	0.349	0.323	0.499	0.426
1:243	0.097	0.109	0.230	0.214	0.132	0.146	0.223	0.219
1:729	0.075	0.083	0.100	0.130	0.099	0.099	0.127	0.136

Antibody concentration ($\mu\text{g/ml}$)	Antigen coating: human CTLA4 at 0.5 $\mu\text{g/ml}$							
	8D2H2L2		8D2H3L3		10D1		11.2.1	
0	0.052	0.055	0.052	0.057	0.056	0.053	0.057	0.061
Secondary antibody	HRP Conjugated Goat Anti Human IgG Secondary Antibody							

Talbe 7. Binding of 8D2H2L2 and 8D2H3L3 to monkey CTLA4 (ELISA)

Antibody concentration ($\mu\text{g/ml}$)	Antigen coating: monkey CTLA4-hFc at 0.25 $\mu\text{g/ml}$							
	8D2H2L2		8D2H3L3		10D1		11.2.1	
1	1.576	1.624	1.235	1.321	1.788	1.846	1.718	1.632
1:3	1.223	1.199	0.921	0.873	1.250	1.344	1.540	1.460
1:9	0.793	0.775	0.654	0.724	0.845	0.868	1.114	1.054
1:27	0.471	0.426	0.441	0.403	0.429	0.402	0.625	0.665
1:81	0.220	0.230	0.239	0.218	0.190	0.191	0.297	0.313
1:243	0.114	0.117	0.123	0.119	0.104	0.108	0.130	0.172
1:729	0.071	0.076	0.088	0.096	0.063	0.067	0.082	0.094
0	0.048	0.048	0.048	0.050	0.049	0.053	0.048	0.051
Secondary antibody	HRP Conjugated Goat Anti Human IgG, F(ab') ₂ Secondary Antibody							

Talbe 8. Binding of 8D2H2L15 and 8D2H2L17 to human CTLA4 (ELISA)

Antibody concentration ($\mu\text{g/ml}$)	Antigen coating: CTLA4 at 0.5 $\mu\text{g/ml}$											
	8D2H2L2 20150327		8D2H2L15		8D2H2L17		10D1		11.2.1		8D2H2L2 20140422	
1	2.34	2.37	2.58	2.55	2.61	2.81	2.56	2.74	2.75	2.69	2.23	2.40
1:3	2.22	2.09	2.65	2.72	2.73	2.78	2.42	2.44	2.56	2.66	2.09	2.07
1:9	2.03	1.87	2.79	2.45	2.59	2.73	2.20	2.20	2.69	2.44	1.92	1.95
1:27	1.82	1.93	2.43	2.21	2.41	2.28	1.81	1.70	2.13	2.28	1.47	1.63
1:81	1.10	1.17	1.95	1.83	1.80	1.68	1.03	1.09	1.37	1.53	1.10	1.01
1:243	0.65	0.58	1.05	1.02	1.14	1.19	0.51	0.53	0.75	0.79	0.49	0.50
1:729	0.26	0.21	0.53	0.44	0.57	0.50	0.21	0.24	0.32	0.31	0.23	0.20
0	0.04	0.05	0.05	0.04	0.04	0.05	0.04	0.05	0.05	0.05	0.05	0.05
Secondary Antibody: HRP Conjugated Goat Anti Human IgG (1:5000)												

Table 9: The binding efficiency, EC₅₀, of 8D2, 8D2(Re) and the 8D2 humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17 to the CTLA4 antigen obtained by curve simulation in the analysis by ELISA

	Source of the CTLA4 antigen	Antibody EC ₅₀ (nM)	10D1 EC ₅₀ (nM)	11.2.1 EC ₅₀ (nM)
8D2	Mouse	0.015	0.062	0.023

	Source of the CTLA4 antigen	Antibody EC ₅₀ (nM)	10D1 EC ₅₀ (nM)	11.2.1 EC ₅₀ (nM)
		0.071	0.24	
8D2(Re)	Mouse	0.015	0.062	0.023
		0.085	0.24	
8D2H1L1	Mouse	0.025	0.062	0.023
8D2H2L2	Human	0.12	0.125	0.09
8D2H2L2	Human	0.082	0.125	0.09
8D2H2L2	Human	0.118	0.125	0.09
8D2H3L3	Human	0.129	0.125	0.09
8D2H2L2	Monkey	0.227	0.258	0.075
8D2H3L3	Monkey	0.385	0.258	0.075
8D2H2L15	Human	0.042	0.138	0.075
8D2H2L17	Human	0.047	0.138	0.075
Note: 8D2H2L2 was measured in triplicate.				

[0140] The above results demonstrate that the antibodies 8D2 and 8D2(Re) bind to the murine CTLA4 antigen with an efficiency better than that of the control antibodies 10D1 and 11.2.1. The humanized antibody 8D2H1L1 binds to the murine CTLA4 antigen with an efficiency stronger than that of the control antibody 10D1 and comparable to that of 11.2.1.

[0141] The humanized antibody 8D2H2L2 binds to the human CTLA4 antigen with an efficiency comparable to that of 10D1. The humanized antibodies 8D2H2L2 and 8D2H3L3 bind to the monkey CTLA4 antigen with an efficiency comparable to that of 10D1. The humanized antibody 8D2H2L15 and 8D2H2L17 bind to the human CTLA4 antigen with an efficiency significantly stronger than that of the control antibodies 10D1 and 11.2.1.

Example 8. Detection of the activity of the antibodies to compete with B7-1/2 for binding to the CTLA4 antigen by competitive ELISA

1. Detection of the activity of the antibodies to compete with B7-1 for binding to the CTLA4 antigen by ELISA

[0142] The ELISA plates were coated with B7-1 at 4 °C overnight. After blocking with 1% BSA at 37 °C for 2 h, the anti-CTLA4 antibodies, i.e., the monoclonal antibodies 8D2 and 8D2(Re) and the 8D2 humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17, as well as the control antibodies 10D1 and 11.2.1 were added. After incubation for

10 minutes, CTLA4-mFc was added. After incubation at 37 °C for 40 minunts, the enzyme conjugated secondary antibody was added. After incubation at 37 °C for 30 minunts, the absorbance at 450 nm was detected on an ELISA plate reader.

2. Detection of the activity of the antibodies to compete with B7-2 for binding to the CTLA4 antigen by ELISA

[0143] The ELISA plates were coated with CTLA4-mFc at 4 °C overnight. After blocking with 1% BSA at 37 °C for 2 h, the anti-CTLA4 antibodies, i.e., the monoclonal antibodies 8D2 and 8D2(Re) and the 8D2 humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17, as well as the control antibodies 10D1 and 11.2.1 were added. After incubation for 10 minutes, B7-2-his was added. After incubation at 37 °C for 40 minunts, the enzyme conjugated secondary antibody was added. After incubation at 37 °C for 30 minunts, the absorbance at 450 nm was detected on an ELISA plate reader. The results of detecting the binding of the 8D2, 8D2(Re) and humanized antibodies to the CTLA4 antigen are shown in Figures 26 to 31, respectively. As shown in the figures, the 8D2, 8D2(Re) antibodies and the 8D2 humanized antibodies could effectively bind to the CTLA pretein, and their binding efficiency is dose-dependent. The fluorescent intensities at each dose are provided in Tables 10 to 16. The binding efficiency, EC₅₀, of 8D2, 8D2(Re) and the humanized antibodies was obtained by curve simulation in the fluorescent quantitative analysis of the bound antibodies 8D2, 8D2(Re) and the humanized antibodies (Table 17).

Table 10. 8D2 and 8D2(Re) compete with B7-1 in ELISA

Antibody concentration (μg/ml)	Antigen coating: CTLA4-mFc at 0.2 μg/ml			
	8D2		8D2(Re)	
3	0.163	0.149	0.176	0.215
1	0.208	0.188	0.200	0.214
0.3	0.354	0.347	0.355	0.390
0.1	0.680	0.695	0.668	0.721
0.03	1.378	1.262	1.430	1.708
0.01	1.758	1.612	1.630	1.824
0.003	1.982	1.711	1.890	1.937
0	2.228	1.766	1.805	1.779
B7/1-hFc (0.3μg/ml)				
Secondary antibody		Goat Anti Human Secondary Antibody		

Table 11. 8D2, 8D2H1L1 and 8D2(Re) compete with B7-1 in ELISA

Antibody concentration (μg/ml)	Coating: B7/1-hFc at 0.2 μg/ml							
	10D1		11.2.1		8D2 H1L1		CTLA4-mFc (0.6 μg/ml) 1:2	
3	0.168	0.158	0.101	0.105	0.123	0.138	0.824	0.791

Antibody concentration (µg/ml)	Coating: B7/1-hFc at 0.2 µg/ml							
	10D1		11.2.1		8D2 H1L1		CTLA4-mFc (0.6 µg/ml) 1:2	
1:3	0.258	0.232	0.119	0.133	0.206	0.231	0.640	0.768
1:9	0.515	0.466	0.381	0.485	0.445	0.529	0.750	0.717
1:27	0.577	0.508	0.597	0.579	0.509	0.659	0.653	0.626
1:81	0.801	0.730	0.650	0.613	0.669	0.723	0.571	0.522
1:243	0.814	0.848	0.900	0.520	0.841	0.821	0.459	0.327
1:729	0.854	0.732	0.993	0.841	0.848	0.822	0.312	0.232
0	0.856	0.812	0.826	0.550	0.672	0.600	0.071	0.074
Antigen	CTLA4-mFc 0.3µg/ml						Control	
Second antibody	HRP Conjugated Goat Anti Mouse IgG Second Antibody							

Table 12. 8D2, 8D2H1L1 and 8D2(Re) compete with B7-2 in ELISA

Antibody concentration µg/ml	Antigen coating: CTLA4-mFc at 0.5 µg/ml									
	10D1		11.2.1		8D2 H1L1		8D2		8D2(Re)	
3	0.569	0.550	0.492	0.442	0.450	0.384	0.407	0.336	0.367	0.375
1:3	0.500	0.466	0.387	0.402	0.404	0.332	0.359	0.306	0.331	0.289
1:9	0.736	0.782	0.412	0.482	0.467	0.371	0.456	0.355	0.384	0.315
1:27	0.982	1.137	0.676	0.585	0.671	0.633	0.675	0.675	0.464	0.443
1:81	1.196	1.355	1.120	0.965	1.038	1.007	1.091	1.050	0.713	0.622
1:243	1.171	1.380	1.237	1.214	1.215	1.069	1.154	1.172	0.862	0.766
1:729	1.307	1.388	1.362	1.229	1.231	1.253	1.242	1.264	0.826	0.725
0	1.030	1.171	1.187	1.100	1.130	1.076	1.034	1.183	0.915	0.861
Receptor	B7/2-His at 1 µg/ml									
Secondary antibody	HRP Conjugated Mouse Anti His Secondary Antibody									

Table 13. The 8D2H2L2 and 8D2H3L3 antibodies compete with B7-1 in ELISA

Antibody concentration (µg/ml)	Coating: B7/1-hFc at 0.3 µg/ml							
	8D2 H2L2		8D2 H3L3		10D1		11.2.1	
5	0.207	0.232	0.187	0.202	0.166	0.172	0.080	0.089
1:3	0.346	0.267	0.286	0.327	0.210	0.194	0.090	0.097
1:9	0.625	0.702	0.416	0.388	0.486	0.548	0.160	0.138
1:27	0.577	0.727	0.590	0.503	0.673	0.621	0.488	0.369
1:81	0.830	0.743	0.747	0.617	0.663	0.647	0.698	0.660
1:243	0.707	0.760	0.673	0.768	0.652	0.775	0.755	0.900
1:729	0.780	0.882	0.840	0.842	0.705	0.691	0.909	0.793

Antibody concentration ($\mu\text{g/ml}$)	Coating: B7/1-hFc at 0.3 $\mu\text{g/ml}$							
	8D2 H2L2		8D2 H3L3		10D1		11.2.1	
0	0.577	0.752	0.632	0.745	0.732	0.909	0.683	0.735
Antigen	CTLA4-mFc at 0.3 $\mu\text{g/ml}$							
Secondary antibody	HRP Conjugated Goat Anti Mouse IgG Secondary Antibody							

Table 14. The 8D2H2L2 and 8D2H3L3 antibodies compete with B7-2 for binding to CTLA4 in ELISA

Antibody concentration ($\mu\text{g/ml}$)	Antigen Coating: CTLA4-mFc at 0.5 $\mu\text{g/ml}$							
	8D2 H2L2		8D2 H3L3		10D1		11.2.1	
1.5	0.377	0.376	0.417	0.432	0.449	0.408	0.372	0.494
1:3	0.616	0.537	0.540	0.511	0.553	0.602	0.437	0.348
1:9	0.988	0.927	0.548	0.614	0.806	0.788	0.479	0.412
1:27	1.085	1.038	0.717	0.728	0.969	0.890	0.622	0.529
1:81	1.227	1.059	1.010	0.951	0.974	0.916	0.805	0.649
1:243	1.136	1.066	1.255	1.160	0.935	0.921	0.930	0.754
1:729	1.218	1.158	1.239	1.162	1.108	1.045	0.981	0.746
0	1.094	1.068	1.198	1.214	1.082	1.047	0.987	0.819
Ligand	B7/2-His at 1 $\mu\text{g/ml}$							
Secondary antibody	HRP Conjugated Mouse Anti His Secondary Antibody							

Table 15. The 8D2H2L15 and 8D2H2L17 antibodies compete with B7-1 for binding to CTLA4 in ELISA

Dilution of Antibody	Antigen coating: B7/1-hFc at 0.5 $\mu\text{g/ml}$											
	8D2 H2L2 (20150327)		8D2 H2L15		8D2 H2L17		10D1		11.2.1		8D2 H2L2 (20140422)	
5 $\mu\text{g/ml}$	0.09	0.10	0.07	0.07	0.06	0.07	0.08	0.11	0.06	0.06	0.12	0.14
1:3	0.13	0.14	0.07	0.07	0.06	0.07	0.33	0.24	0.09	0.08	0.26	0.24
1:9	0.29	0.26	0.07	0.09	0.08	0.08	0.71	0.78	0.33	0.30	0.45	0.49
1:27	0.66	0.58	0.70	1.03	0.89	0.93	1.11	1.17	1.14	1.19	1.06	1.10
1:81	0.69	0.62	0.68	1.18	0.97	0.79	1.16	1.35	1.17	1.20	1.09	1.09
1:243	0.66	0.64	0.75	1.13	1.05	0.99	1.27	1.48	1.30	1.31	1.19	0.99
1:729	0.69	0.64	0.74	1.07	1.25	1.35	1.33	1.56	1.32	1.31	1.16	1.12
0	0.59	0.66	0.53	1.09	1.18	1.18	1.33	1.29	1.28	1.30	1.11	1.04
Ligand	CTLA4-mFc at 0.3 $\mu\text{g/ml}$											
Secondary antibody	HRP Conjugated Mouse Anti His Secondary Antibody											

Table 16. The 8D2H2L15 and 8D2H2L17 antibodies compete with B7-2 for binding to CTLA4 in

ELISA

Dilution of Antibody	CTLA4-mFc at 2 µg/ml											
	8D2H2L2 20140422		8D2H2L15		8D2H2L17		10D1		11.2.1		8D2H2L2 20150327	
1 µg/ml	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.04	0.04	0.05	0.05
1:3	0.05	0.05	0.05	0.05	0.05	0.05	0.07	0.07	0.05	0.05	0.47	0.37
1:9	0.15	0.16	0.17	0.19	0.06	0.12	0.44	0.35	0.17	0.16	0.65	0.58
1:27	0.55	0.59	0.42	0.48	0.50	0.57	0.73	0.70	0.57	0.57	0.79	0.70
1:81	0.76	0.84	0.75	0.75	0.77	0.81	0.85	0.86	0.84	0.76	0.86	0.77
1:243	0.84	0.79	0.83	0.84	0.82	0.87	0.86	0.89	0.84	0.85	0.83	0.84
1:729	0.77	0.76	0.94	1.00	0.97	0.98	0.99	0.91	0.87	0.85	0.82	0.80
0	0.77	0.78	0.92	0.97	0.81	0.82	0.76	0.96	0.91	0.80	0.80	0.76
Ligand	B7/2-His, 0.5 µg/ml											
Secondary antibody	HRP Conjugated Mouse Anti His Secondary Antibody (1:4000)											

Table 17. The binding efficiency, EC_{50} , of 8D2, 8D2(Re) and the 8D2 humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17 to the CTLA4 antigen in competition with B7 obtained by curve simulation in the analysis by competitive ELISA

	Antibody EC_{50} (nM)		10D1 EC_{50} (nM)		11.2.1 EC_{50} (nM)	
	B7-1	B7-2	B7-1	B7-2	B7-1	B7-2
8D2	0.44	0.208	-	0.464	-	0.15
8D2(Re)	0.514	0.153	-	0.464	-	0.15
8D2H1L1	2.478	0.178	1.91	0.464	1.691	0.15
8D2H2L2	5.932	1.643	5.15	2.056	1.073	0.172
8D2H2L2	2.973	0.368	-	-	-	-
8D2H2L2	3.118	0.301	-	-	-	-
8D2H3L3	2.144	0.167	5.15	2.056	1.073	0.172
8D2H2L15	1.973	0.227	4.586	0.629	2.606	0.349
8D2H2L17	1.787	0.296	4.586	0.629	2.606	0.349

Note: 8D2H2L2 was tested in triplicate.

[0144] The above results demonstrated that the antibodies 8D2, 8D2 (Re) and the 8D2 humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17 all can compete with B7 for binding to the CTLA4 antigen. Particularly, 8D2, 8D2(Re), 8D2H1L1, and 8D2H2L2 are stronger than 10D1 in competing with B7-2 for binding to CTLA4, while 8D2H2L17 is stronger than the antibodies 10D1 and 11.2.1 in competing with both of B7-1 and B7-2 for binding to CTLA4.

Example 9. Analysis of the biological activities of the monoclonal antibody 8D2 and the humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17 in cells

[0145] To detect the effect of the monoclonal antibody 8D2 and the humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17, and the control antibodies 10D1 and 11.2.1 on the IL-2 expression of peripheral blood mononuclear cells (PBMC's), peripheral blood from healthy donors was collected into collection tubes containing heparin sodium. PBMC's were obtained as a cell suspension after dilution in PBS and centrifugation on separation medium (at 2550 rpm for 20 min). The cell suspension was added with SEB (1 $\mu\text{g/mL}$) / PHA (30 $\mu\text{l/ml}$) and placed in an incubator at 37 °C with saturated humidity containing 5% CO₂ for further culture. Raji lymphocytes and the antibody were added. After co-incubation for 48 hours, PBMC's were washed with PBS twice, and were added to 96 well plates at 10,000 cell/well. Then, the corresponding concentration gradient of the antibodies was added. After incubation for 20 minutes, Raji cells treated with MMC for 1 hour were added at 10,000 cell/well for co-culture of 72 hours. After co-culture for 72 hours, the cell culture was collected for supernatant and the IL-2 expression profile in the supernatant of the cell co-culture was detected using an ELISA kit following the instructions provided with the kit (Dakewe Co., DKW12-1020-096).

[0146] After statistic analysis, the results of the experiments are showed in Figures 32 and 33. As compared with the T cell group and the Raji cell group, for the monoclonal antibody 8D2, all its humanized antibodies 8D2H1L1, 8D2H2L2, 8D2H3L3, 8D2H2L15, and 8D2H2L17 can effectively block binding of CTLA4 to B7 and improve the IL-2 expression in T lymphocytes (Figures 32 and 33). Particularly, the inventor surprisingly discovered that 8D2H2L2, 8D2H2L15 and 8D2H2L17 are significantly superior than the control antibodies 10D1 and 11.2.1. At the concentration of 10 nM, they achieved an IL-2 level comparable or even better than that achieved by 10D1 or 11.2.1 at the concentration of 100 nM. Thus, the antibodies of the present invention can increase the level of IL-2 at a lower concentration, e.g., about 10 nM.

Example 10. The *in vivo* anti-tumor activity of the monoclonal antibody 8D2H2L2

[0147] The *in vivo* anti-tumor activity of 8D2H2L2 was evaluated using the hu-SCID-raji animal model. Human peripheral blood mononuclear cells (PBMC's) were isolated using the Ficoll reagent, and activated using SEB at 1 $\mu\text{g/ml}$ for 3 days. Then, 1.25×10^6 activated PBMC's were mixed with 5×10^6 Raji Burkitt lymphoma cells and 8D2H2L2 (20 mg/kg), and were injected subcutaneously on the back of SCID-beige mice. At the same time, an isotype control group was set up, 5 animals per group. Subsequently, a dose of 20 mg/kg was administered by intravenous injection once a week for three consecutive weeks. The tumor volume was measured twice a week until the end of the experiments or when the tumor volume reached 1000 mm³.

[0148] As shown in Figure 34, 8D2H2L2 could notably inhibit tumor growth in the hu-SCID-raji model. This result indicated that this antibody can be used clinically to treat lymphoma.

[0149] While the specific embodiments of the invention have been described in details, those skilled in the art, in light of the teaching disclosed in the specification, will understand that various changes and modifications can be made to the details. The full scope of the invention is set forth in the appended claims.

Sequence Listing

[0150]

<110> AKESO BIOPHARMA, INC.

<120> ANTI-CTLA4 MONOCLONAL ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF,
MEDICINAL COMPOSITION AND USE

<130> IEC150044PCT

<150> 201410377352.9

<151> 2014-08-01

<160> 34

<170> PatentIn version 3.2

<210> 1

<211> 375

<212> DNA

<213> Artificial sequence

<220>

<223> the nucleic acid sequence encoding the CTLA4ECD protein

<400> 1

gcaatgcacg tggcccagcc tgctgtggtg ctggccagca gccgaggcat cggcagcttt	60
gtgtgtgagt atgcatctcc aggcaaagcc actgaggtcc gggtgacagt gcttcggcag	120
gctgacagcc aggtgactga agtctgtgcg gcaacctaca tgatggggaa tgagttgacc	180
ttcctagatg attccatctg cacgggcacc tccagtggaa atcaagtga cctcactatc	240
caaggactga gggccatgga cacgggactc tacatctgca aggtggagct catgtacca	300
ccgccatact acctgggcac aggcacacga acccagattt atgtaattga tccagaaccg	360
tgcccagatt ctgac	375

$\langle 210 \rangle$ 2

<211> 125

<212> PRT

<213> Artificial sequence

$\langle 220 \rangle$

<223> the amino acid sequence of the CTLA4ECD protein

$\langle 400 \rangle$ 2

Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly
1 5 10 15

Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu
20 25 30

Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val
35 40 45

Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp Asp

50 55 60

Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile
65 70 75 80

Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu
85 90 95

Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln
100 105 110

Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp
115 120 125

$\langle 210 \rangle$ 3

<211> 364

<212> PRT

<213> Artificial sequence

$\langle 220 \rangle$

<223> the amino acid sequence of the CTLA4ECD-mFc chimeric protein

$\langle 400 \rangle$ 3

Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly
1 5 10 15

Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu
20 25 30

Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val
35 40 45

Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp Asp

50					55					60					
Ser	Ile	Cys	Thr	Gly	Thr	Ser	Ser	Gly	Asn	Gln	Val	Asn	Leu	Thr	Ile
65					70					75					80
Gln	Gly	Leu	Arg	Ala	Met	Asp	Thr	Gly	Leu	Tyr	Ile	Cys	Lys	Val	Glu
				85					90					95	
Leu	Met	Tyr	Pro	Pro	Pro	Tyr	Tyr	Leu	Gly	Ile	Gly	Asn	Gly	Thr	Gln
			100					105					110		
Ile	Tyr	Val	Ile	Asp	Pro	Glu	Pro	Cys	Pro	Asp	Ser	Asp	Glu	Asn	Leu
		115					120					125			
Tyr	Phe	Gln	Gly	Pro	Arg	Gly	Pro	Thr	Ile	Lys	Pro	Cys	Pro	Pro	Cys
	130					135					140				
Lys	Cys	Pro	Ala	Pro	Asn	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Ile	Phe
145					150					155					160
Pro	Pro	Lys	Ile	Lys	Asp	Val	Leu	Met	Ile	Ser	Leu	Ser	Pro	Ile	Val
				165					170					175	
Thr	Cys	Val	Val	Val	Asp	Val	Ser	Glu	Asp	Asp	Pro	Asp	Val	Gln	Ile
			180					185					190		
Ser	Trp	Phe	Val	Asn	Asn	Val	Glu	Val	His	Thr	Ala	Gln	Thr	Gln	Thr
		195					200					205			
His	Arg	Glu	Asp	Tyr	Asn	Ser	Thr	Leu	Arg	Val	Val	Ser	Ala	Leu	Pro
	210					215					220				
Ile	Gln	His	Gln	Asp	Trp	Met	Ser	Gly	Lys	Glu	Phe	Lys	Cys	Lys	Val
225					230					235					240
Asn	Asn	Lys	Asp	Leu	Pro	Ala	Pro	Ile	Glu	Arg	Thr	Ile	Ser	Lys	Pro
				245					250					255	
Lys	Gly	Ser	Val	Arg	Ala	Pro	Gln	Val	Tyr	Val	Leu	Pro	Pro	Pro	Glu
			260					265					270		
Glu	Glu	Met	Thr	Lys	Lys	Gln	Val	Thr	Leu	Thr	Cys	Met	Val	Thr	Asp
		275					280					285			
Phe	Met	Pro	Glu	Asp	Ile	Tyr	Val	Glu	Trp	Thr	Asn	Asn	Gly	Lys	Thr
	290					295					300				
Glu	Leu	Asn	Tyr	Lys	Asn	Thr	Glu	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser
305					310					315					320
Tyr	Phe	Met	Tyr	Ser	Lys	Leu	Arg	Val	Glu	Lys	Lys	Asn	Trp	Val	Glu
				325					330					335	
Arg	Asn	Ser	Tyr	Ser	Cys	Ser	Val	Val	His	Glu	Gly	Leu	His	Asn	His
			340					345					350		

His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
355 360

<210> 4
<211> 1092
<212> DNA
<213> Artificial sequence

<220>
<223> the nucleic acid sequence encoding the CTLA4ECD-mFc chimeric protein

<400> 4
gcaatgcatg tgcacagcc tgcagtggtc ctggcaagct ccaggggaat cgctagcttc 60
gtgtgcgaat acgcttcccc aggcaaggca accgaggtcc gggtgacagt cctgagacag 120
gccgacagcc aggtgacaga agtctgcgcc gctacttata tgatgggcaa cgagctgacc 180
tttctggacg atagcatttg taccgggaca tctagtggaa accaagtgaa tctgaccatc 240
cagggcctgc gcgctatgga cacagggctg tacatttgta aagtggagct gatgtatccc 300
cctccatact atctgggaat cggcaacggg acccagatct acgtgattga tcctgaacca 360
tgccccgact ccgatgagaa tctgtatttc cagggaccac gagggcccac aattaagcca 420
tgtccccctt gcaaagtgtc tgcaccaaac ctgctgggag gaccaagcgt gttcatcttt 480
ccaccaaga tcaaggacgt gctgatgatc tctactgacc ccattgtgac ctgcgtggtc 540
gtggacgtga gcgaggacga tcctgatgtg cagatcagtt ggttcgtcaa caatgtggaa 600
gtccacacag ctcagactca gacccatagg gaggattaca atagtactct gcgcgtcgtg 660
tcagcactgc ccattcagca ccaggactgg atgagcggca aggagttcaa gtgcaaagtg 720
aacaacaagg atctgcccgc acctatcgag agaactatth ccaagcctaa agggctctgtg 780
agggcccccac aggtgtatgt cctgcctcca cccgaggaag agatgactaa gaaacagggtg 840
aactgacttt gtatggtcac cgacttcatg cccgaagata tctacgtgga gtggactaac 900
aatgggaaga ccgaactgaa ctataaaaat acagagcctg tgctggactc agatggaagc 960
tactttatgt atagcaagct gcgagtggaa aagaaaaact gggtcgagcg gaacagctac 1020
tcttgtagtg tgggccacga agggctgcat aatcaccaca ccactaaatc attctcccga 1080
actccaggca aa 1092

<210> 5
<211> 345
<212> DNA
<213> Artificial sequence

<220>
<223> the nucleic acid sequence encoding the heavy chain variable domain of the monoclonal antibody 8D2

<400> 5
gaggtgaaac tggacgaaac tggcgggggg ctggtgcagc ccggacgacc tatgaagctg 60
tactactatc cagggccttc cagcttctac cagggccttc tgcatttact cagggccttc 120

```

tcattgctcg ccagcgggtt cacccttagc gacaactgga tgaattgggt gaggcagagc   120
ccagagaagg ggctggaatg gctgggtcag atccgcaaca aaccctacaa ttatgagacc   180
tactattctg acagtgtgaa gggccgggtt acaatttcca gagacgattc taaaagctcc   240
gtctacctgc agatgaacaa tctgagaggc gaagatatgg ggatctacta ttgcacagca   300
cagttcgctt attggggaca gggcactctg gtcacagtct ccgcc                      345

```

<210> 6

<211> 115

<212> PRT

<213> Artificial sequence

<220>

<223> the amino acid sequence of the heavy chain variable domain of the monoclonal antibody 8D2

<400> 6

```

Glu Val Lys Leu Asp Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Arg
1           5           10           15

Pro Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Asn
          20           25           30

Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Leu
          35           40           45

Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp
          50           55           60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
65           70           75           80

Val Tyr Leu Gln Met Asn Asn Leu Arg Gly Glu Asp Met Gly Ile Tyr
          85           90           95

Tyr Cys Thr Ala Gln Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
          100          105          110

Val Ser Ala
          115

```

<210> 7

<211> 318

<212> DNA

<213> Artificial sequence

<220>

<223> the nucleic acid sequence encoding the light chain variable domain of the monoclonal antibody 8D2

<400> 7

```

gacattcaga tgacacagag tcctgcttcc ctgagtgcct cagtggggga gaccgtcaca   60

```

atcacttgcg gcacctctga aaacatctac ggcgggctga attggtatca gcggaagcag 120
ggcaaaagtc cccagctgct gatcttcgga gcaacaaacc tggccgacgg catgagctcc 180
cggtttagcg ggtccggatc tggcagacag tacagcctga agatttctag tctgcaccca 240
gacgatgtgg ctacttacta ttgccagaat gtcctgagga gtcccttcac ctttgggtca 300
ggaacaaagc tggagatc 318

<210> 8
<211> 106
<212> PRT
<213> Artificial sequence

<220>
<223> the amino acid sequence of the light chain variable domain of the monoclonal antibody 8D2

<400> 8
Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Glu Thr Val Thr Ile Thr Cys Gly Thr Ser Glu Asn Ile Tyr Gly Gly
20 25 30

Leu Asn Trp Tyr Gln Arg Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile
35 40 45

Phe Gly Ala Thr Asn Leu Ala Asp Gly Met Ser Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Arg Gln Tyr Ser Leu Lys Ile Ser Ser Leu His Pro
65 70 75 80

Asp Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Arg Ser Pro Phe
85 90 95

Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile
100 105

<210> 9
<211> 345
<212> DNA
<213> Artificial sequence

<220>
<223> the nucleic acid sequence encoding the heavy chain variable domain of the monoclonal antibody 8D2H1L1

<400> 9
gaagtgcagc tggtcgagtc cgggggggggc ctggtgcagc caggaggatc aatgcgactg 60
agctgcgccg cttccggctt caccttcagc gacaactgga tgaattgggt caggcaggca 120

ccaggaaagg gactggagtg gctggcacag atccgcaaca aaccttaca ctacgaaact 180
tactacagcg actccgtgaa ggggcggttc accatttcta gagacgattc taaaaacagt 240
gtgtacctgc agatgaatag cctgaagacc gaggatacag gagtctacta ttgtaccgca 300
cagtttgctt attgggggca gggcactctg gtgacagtct cttca 345

<210> 10
<211> 115
<212> PRT
<213> Artificial sequence

<220>
<223> the amino acid sequence of the light chain variable domain of the monoclonal antibody 8D2H1L1

<400> 10
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Asn
20 25 30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45

Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Gly Val Tyr
85 90 95

Tyr Cys Thr Ala Gln Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
100 105 110

Val Ser Ser
115

<210> 11
<211> 321
<212> DNA
<213> Artificial sequence

<220>
<223> the nucleic acid sequence encoding the light chain variable domain of the monoclonal antibody 8D2H1L1

<400> 11
gacattcaga tgactcagag cccttcaagc ctgtccgcat ctgtgggcga ccgagtcacc 60
...

```

atcacatgca gaacctccga gaacatctac ggcggggtga attggtatca gcgaaagcag    120
gggaaaagtc ccaagctgct gatctacggg gcaacaaacc tggccagcgg aatgagctcc    180
agattcagtg gatcaggcag cgggacagat tatactctga aaatttctag tctgcaccca    240
gacgatgtgg caacctacta ttgccagaat gtcctgaggt cacccttcac ctttggaagc    300
ggcacaaaac tggagatcaa g                                           321

```

<210> 12

<211> 107

<212> PRT

<213> Artificial sequence

<220>

<223> the amino acid sequence of the light chain variable domain of the monoclonal antibody 8D2H1L1

<400> 12

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1           5           10          15

```

```

Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Ile Tyr Gly Gly
20          25          30

```

```

Leu Asn Trp Tyr Gln Arg Lys Gln Gly Lys Ser Pro Lys Leu Leu Ile
35          40          45

```

```

Tyr Gly Ala Thr Asn Leu Ala Ser Gly Met Ser Ser Arg Phe Ser Gly
50          55          60

```

```

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Lys Ile Ser Ser Leu His Pro
65          70          75          80

```

```

Asp Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Arg Ser Pro Phe
85          90          95

```

```

Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100          105

```

<210> 13

<211> 345

<212> DNA

<213> Artificial sequence

<220>

<223> the nucleic acid sequence encoding the heavy chain variable domain of the monoclonal antibody 8D2H2L2, 8D2H2L15 or 8D2H2L17

<400> 13

```

gaagtgcagc tggtcgagtc cgggggggggc ctggtgcagc caggaggatc aatgcgactg    60

```

```

agctgcgccg cttccggctt cacccttcagc gacaactgga tgaattgggt caggcaggca    120

```

```

cagggaaagg cactggactg gctggcagag atggggaaga aactttagaa ctacgaaagt    180

```

ccaggaaagc gactggagtc gctggcaccg attcgcaca aaccttaca ctagaaact 180
tactacagcg cctccgtgaa ggggcgggtc accatttcta gagacgattc taaaaacagt 240
gtgtacctgc agatgaatag cctgaagacc gaggatacag gagtctacta ttgtaccgca 300
cagtttgctt attgggggca gggcactctg gtgacagtct cttca 345

<210> 14
<211> 115
<212> PRT
<213> Artificial sequence

<220>
<223> the amino acid sequence of the heavy chain variable domain of the monoclonal antibody 8D2H2L2, 8D2H2L15 or 8D2H2L17

<400> 14
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Asn
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Ala
50 55 60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser
65 70 75 80
Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Gly Val Tyr
85 90 95
Tyr Cys Thr Ala Gln Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
100 105 110
Val Ser Ser
115

<210> 15
<211> 321
<212> DNA
<213> Artificial sequence

<220>
<223> the nucleic acid sequence encoding the light chain variable domain of the monoclonal antibody 8D2H2L2

<400> 15
gacattcaga tgactcagag cccttcaagc ctgagtgcct cagtgggaga ccgggtcacc 60
atcacatgca gaaccagcga gaacatctac ggcggcctga actggtatca gcgaaagcca 120

ggcaagagcc ccaagctgct gatctacggg gcaaccaacc tggcctctgg agtgagctcc 180
 agattcagcg gcagcgggctc tgggaccgac tatactctga ccatttctag tctgcagcct 240
 gaagatgtgg caacatacta ttgccagaat gtcctgaggt cccattcac ctttgatct 300
 ggcaccaagc tggagatcaa g 321

<210> 16

<211> 107

<212> PRT

<213> Artificial sequence

<220>

<223> the amino acid sequence of the light chain variable domain of the monoclonal antibody 8D2H2L2

<400> 16

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Ile Tyr Gly Gly
 20 25 30

Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile
 35 40 45

Tyr Gly Ala Thr Asn Leu Ala Ser Gly Val Ser Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Arg Ser Pro Phe
 85 90 95

Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 17

<211> 345

<212> DNA

<213> Artificial sequence

<220>

<223> the nucleic acid sequence encoding the heavy chain variable domain of the monoclonal antibody 8D2H3L3

<400> 17

gaggtgcagc tggtcgagtc tggaggcggc ctggtgcagc ccggcgggctc actgagactg 60

agctgcgccg cttccgggctt caccttcagc gacaactgga tgaattgggt gaggcaggca 120

cccgggaagg ggctggagtg ggtcgctcag atccgcaaca aaccttaca ttatgagaca 180

gaatacgcag cctctgtgaa ggggcgggttc actattagta gagacgatag caagaacagc 240
gcctatctgc agatgaatag cctgaagacc gaagatacag ccgtctacta ttgtacagct 300
cagtttgcac actggggcca ggggaactctg gtgaccgtca gctcc 345

<210> 18

<211> 115

<212> PRT

<213> Artificial sequence

<220>

<223> the amino acid sequence of the heavy chain variable domain of the monoclonal antibody 8D2H3L3

<400> 18

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Asn
20 25 30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Glu Tyr Ala Ala
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser
65 70 75 80

Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Thr Ala Gln Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
100 105 110

Val Ser Ser
115

<210> 19

<211> 321

<212> DNA

<213> Artificial sequence

<220>

<223> the nucleic acid sequence encoding the light chain variable domain of the monoclonal antibody 8D2H3L3

<400> 19

gacattcaga tgactcagag cccttcttct ctgtccgcat ctgtgggaga ccgggtcacc 60

atcacatgca gagccagcga gaacatctac ggcggcctga actggtatca gcagaagcca 120

ggcaaagctc ccaagctgct gatctacgga gcaacctccc tggcatctgg agtgccatcc 180
cggttcagtg gatcaggcag cgggaccgac tatactctga ccattagctc cctgcagcct 240
gaagacttcg ccacatacta ttgccagaac gtgctgaggt ccccatcac ctttggatct 300
ggcaccaagc tggagatcaa g 321

<210> 20
<211> 107
<212> PRT
<213> Artificial sequence

<220>
<223> the amino acid sequence of the light chain variable domain of the monoclonal antibody 8D2H3L3

<400> 20
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Gly Gly
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Thr Ser Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Val Leu Arg Ser Pro Phe
85 90 95

Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 21
<211> 321
<212> DNA
<213> Artificial sequence

<220>
<223> the nucleic acid sequence encoding the light chain variable domain of the monoclonal antibody 8D2H2L15

<400> 21
gacatccaga tgactcagtc tcccagctcc ctgtccgctt ctgtggggcga tcgggtcact 60

atcacctgta gaaccagcga gaacatttac ggcggactga attggtatca gaggaagccc 120

gggaaaagtc ctaagctgct gatctacgga gcaacaaacc tggcctccgg cgtgtctagt 180
... .. 240

cgcttcagtg gatcaggcag cgggaccgac tatacactga ctatttcaag cctgcagcca 240
gaggatgtgg ccacatacta ttgccagaat gtcctgagcc ggcaccccgg atttggctca 300
gggaccaaac tggaattaa g 321

<210> 22

<211> 107

<212> PRT

<213> Artificial sequence

<220>

<223> the amino acid sequence of the light chain variable domain of the monoclonal antibody 8D2H2L15

<400> 22

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Ile Tyr Gly Gly
20 25 30

Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Thr Asn Leu Ala Ser Gly Val Ser Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Ser Arg His Pro
85 90 95

Gly Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 23

<211> 321

<212> DNA

<213> Artificial sequence

<220>

<223> the nucleic acid sequence encoding the light chain variable domain of the monoclonal antibody 8D2H2L17

<400> 23

gacatccaga tgactcagtc acccagctcc ctgagtgctt cagtgggcga tcgggtcact 60

atcacctgta gaaccagcga gaacatttac ggcggactga attggtatca gaggaagccc 120

gggaaaagcc ctaagctgct gatctacgga gcaacaaacc tggcctccgg cgtgtctagt 180

cgcttcagcg gcagcggctc tggaaccgac tatacactga ctatttcaag cctgcagcca 240

gagatataa ccacatacta ttaccagaat atcctatcct ctccacccaa atttaacaa 300

gggaccaaac tggaaattaa g 321

<210> 24
<211> 107
<212> PRT
<213> Artificial sequence

<220>
<223> the amino acid sequence of the light chain variable domain of the monoclonal antibody 8D2H2L17

<400> 24
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Ile Tyr Gly Gly
20 25 30

Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Thr Asn Leu Ala Ser Gly Val Ser Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Ser Ser Arg Pro
85 90 95

Gly Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 25
<211> 636
<212> DNA
<213> Artificial sequence

<220>
<223> the nucleic acid sequence encoding the CTLA4 protein

<400> 25
atgggcgtcc tgctgactca gagaaccctg ctgtccctgg tgctggcact gctgtttcct 60
tcaatggctt caatggctat gcatgtggct cagccagcag tggtcctggc aagctccagg 120
gggatcgcca gtttcgtgtg cgagtacgcc tcacctggaa aggctacaga agtccgggtg 180
actgtcctga gacaggctga ctctcaggtg accgaggtct ggcgcgctac atatatgatg 240
ggcaacgaac tgacctttct ggacgattcc atttgtactg gcacctctag tgggaaccaa 300
gtgaatctga ctatccaggg actgcgagca atggacaccg gactgtacat ttgcaaagtg 360
gagctgatgt atccccctcc atactatctg ggcacgggga atggaacaca gatctacgtg 420

```

attgatcccg aaccttgtcc agacagcgat ttctgtgtgt ggattctggc agccgtgtca 480
agcggcctgt tcttttatag ctttctgctg actgccgtct cctgtcttaa gatgctgaag 540
aaacgatccc cctgaccac aggggtggtc gtgaaaatgc cacctaccga gcccgagtgc 600
gaaaaacagt tccagccata ctttatccct atcaat 636

```

<210> 26

<211> 212

<212> PRT

<213> Artificial sequence

<220>

<223> the amino acid sequence of the CTLA4 protein

<400> 26

```

Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala
1          5          10          15

Leu Leu Phe Pro Ser Met Ala Ser Met Ala Met His Val Ala Gln Pro
20          25          30

Ala Val Val Leu Ala Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu
35          40          45

Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg
50          55          60

Gln Ala Asp Ser Gln Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met
65          70          75          80

Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser
85          90          95

Ser Gly Asn Gln Val Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp
100         105         110

Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr
115         120         125

Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu
130         135         140

Pro Cys Pro Asp Ser Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser
145         150         155         160

Ser Gly Leu Phe Phe Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu Ser
165         170         175

Lys Met Leu Lys Lys Arg Ser Pro Leu Thr Thr Gly Val Val Val Lys
180         185         190

Met Pro Pro Thr Glu Pro Glu Cys Glu Lys Gln Phe Gln Pro Tyr Phe
195         200         205

```

Ile Pro Ile Asn
210

<210> 27

<211> 8

<212> PRT

<213> Artificial sequence

<220>

<223> the amino acid sequence of CDR

<400> 27

Gly Phe Thr Phe Ser Asp Asn Trp
1 5

<210> 28

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> the amino acid sequence of CDR

<400> 28

Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr
1 5 10

<210> 29

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<223> the amino acid sequence of CDR

<400> 29

Thr Ala Gln Phe Ala Tyr
1 5

<210> 30

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<223> the amino acid sequence of CDR

<400> 30

Glu Asn Ile Tyr Gly Gly
1 5

<210> 31
 <211> 3
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> the amino acid sequence of CDR

 <400> 31
 Gly Ala Thr
 1

 <210> 32
 <211> 9
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> the amino acid sequence of CDR

 <400> 32
 Gln Asn Val Leu Arg Ser Pro Phe Thr
 1 5

 <210> 33
 <211> 9
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> the amino acid sequence of CDR

 <400> 33
 Gln Asn Val Leu Ser Arg His Pro Gly
 1 5

 <210> 34
 <211> 9
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> the amino acid sequence of CDR

 <400> 34
 Gln Asn Val Leu Ser Ser Arg Pro Gly
 1 5

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US6984720B1 [0003] [0073] [0080] [0138]
- US6682736B1 [0003] [0080]
- US4816567A [0053] [0055]
- US682736B1 [0073] [0138]

Non-patent literature cited in the description

- GROSSO JF.JURE-KUNKEL MNCancer Immun., 2013, vol. 13, 5- [0003]
- CHAVEZ, A.R. et al.Ann N Y Acad Sci, 2009, vol. 1182, 14-27 [0004]
- KABAT et al.Sequences of Proteins of Immunological InterestNIH Publication 91-324219910000vol. 1-3, [0019]
- KABATSequences of Proteins of Immunological InterestNational Institutes of Health19870000 [0046]
- CHOTHIALESKJ. Mol. Biol., 1987, vol. 196, 901-917 [0046]
- CHOTHIA et al.Nature, 1989, vol. 342, 878-883 [0046]
- Fundamental ImmunologyRaven Press19890000 [0047]
- WARD et al.Nature, 1989, vol. 341, 544-546 [0048]
- BIRD et al.Science, 1988, vol. 242, 423-426 [0049]
- HUSTON et al.Proc. Natl. Acad. Sci. USA, 1988, vol. 85, 5879-5883 [0049]
- HOLLIGER et al.Proc. Natl. Acad. Sci. USA, 1993, vol. 90, 6444-6448 [0049]
- ALFTHAN et al.Protein Eng., 1995, vol. 8, 725-731 [0049]
- CHOI et al.Eur. J. Immunol., 2001, vol. 31, 94-106 [0049]
- HU et al.Cancer Res., 1996, vol. 56, 3055-3061 [0049]
- KIPRIYANOV et al.J. Mol. Biol., 1999, vol. 293, 41-56 [0049]
- ROOVERS et al.Cancer Immunol., 2001, [0049]
- HOLLIGER P. et al.Proc. Natl. Acad. Sci. USA, 1993, vol. 90, 6444-6448 [0050]
- POLJAK R. J. et al.Structure, 1994, vol. 2, 1121-1123 [0050]
- KOHLER et al.Nature, 1975, vol. 256, 495- [0053]
- MORRISON et al.Proc. Natl. Acad. Sci. USA, 1984, vol. 81, 6851-6855 [0055]

- JONES et al. Nature, 1986, vol. 321, 522-525 [0056]
- REICHMANN et al. Nature, 1988, vol. 332, 323-329 [0056]
- PRESTA Curr. Op. Struct. Biol., 1992, vol. 2, 593-596 [0056]
- CLARK Immunol. Today, 2000, vol. 21, 397-402 [0056]
- Epitope Mapping Protocols in Methods in Molecular Biology 19960000 vol. 66, [0058]
- NEEDLEMAN et al. J. Mol. Biol., 1970, vol. 48, 443-453 [0063]
- E. MEYERSW. MILLER Comput. Appl. Biosci., 1988, vol. 4, 11-17 [0063]
- NEEDLEMAN WUNSCH J Mol Biol., 1970, vol. 48, 444-453 [0063]
- BRUMMELL et al. Biochem., 1993, vol. 32, 1180-1187 [0064]
- KOBAYASHI et al. Protein Eng., 1999, vol. 12, 10879-884 [0064]
- BURKS et al. Proc. Natl. Acad. Sci. USA, 1997, vol. 94, 412-417 [0064]
- Remington's Pharmaceutical Sciences Mack Publishing Company 19950000 [0070]
- PEITANG HUANG et al. Molecular Cloning: A Laboratory Manual Science Press [0077]
- Monoclonal Antibody Production STEWART, S. J. Basic Methods in antibody Production and Characterization CRC Press 20000000 [0092]
- Nat. Struct. Biol., 1997, vol. 4, 527- [0102]

PATENTKRAV

1. Et antistof eller antigenbindende fragment deraf, der binder til human CTLA4, udvalgt blandt gruppen bestående af:

5

(a) et antistof eller antigenbindende fragment deraf omfattende en tung kæde variabel region af SEQ ID NO: 14 og en let kæde variabel region af SEQ ID NO: 16; og

10

(b) et antistof eller antigenbindende fragment deraf omfattende en tung kæde variabel region af SEQ ID NO: 14 og en let kæde variabel region af SEQ ID NO: 16, hvor i SEQ ID NO: 14 i position 18 kan methioninen være substitueret med en aminosyre udvalgt fra gruppen bestående af: leucin, valin, isoleucin og alanin.

15

2. Antistof eller antigenbindende fragment ifølge krav 1, hvor methioninen i position 18 i SEQ ID NO: 14 er substitueret med leucin og en let kæde variabel region af SEQ ID NO: 16.

20

3. Antistof eller antigenbindende fragment deraf ifølge krav 1 eller 2, hvilket er et humaniseret antistof eller antigenbindende fragment deraf.

25

4. Antistof eller antigenbindingsfragment deraf ifølge et hvilket som helst af kravene 1-3, hvor antistoffet eller antigenbindingsfragmentet deraf binder til human CTLA4 med en K_D mindre end ca. 10^{-5} M som bestemt ved overfladeplasmonresonans.

30

5. Antistof eller antigenbindende fragment deraf ifølge ethvert af kravene 1-4, hvor antistoffet eller antigenfragmentet deraf:

(a) blokerer bindingen af human CTLA4 til human B7;

(b) regulerer aktiviteten af human CTLA4;

(c) afhjælper immunsuppressionen på kroppen ved hjælp af human CTLA4;

(d) aktiverer T-lymfocytter og/eller

(e) forøger ekspressionen af IL-2 i T-lymfocytter.

6. Et eller flere isolerede nukleinsyremolekyler kodende for et antistof eller antigenbindende fragment ifølge krav 1.
- 5 7. Den ene eller flere isolerede nukleinsyremolekyler ifølge krav 6, hvor den ene eller flere isolerede nukleinsyremolekyler har nukleotidsekvensen som beskrevet i SEQ ID NO: 13 eller SEQ ID NO: 15.
8. En vektor omfattende det isolerede nukleinsyremolekyle ifølge krav 6.
- 10 9. En værtscelle omfattende vektoren ifølge krav 8.
- 15 10. Fremgangsmåde til fremstilling af antistoffet eller antigenbindingsfragmentet deraf ifølge et hvilket som helst af kravene 1 til 4, omfattende trinnene til dyrkning af værtscellen ifølge krav 8 under egnede betingelser og udvinding af antistoffet eller antigenbindingsfragmentet deraf fra cellekulturen.
- 20 11. Farmaceutisk sammensætning omfattende antistoffet eller antigenbindingsfragmentet deraf ifølge et hvilket som helst af kravene 1-5 og en farmaceutisk acceptabel bærer og/eller excipients.
- 25 12. Antistof eller antigenbindingsfragment deraf ifølge et hvilket som helst af kravene 1 til 5 til anvendelse i en fremgangsmåde til behandling af cancer, såsom melanom, nyretumor/renaltumor, prostatacancer, blærecancer, kolorektal cancer, gastrointestinalkanal cancer og/eller lever cancer/hepatisk cancer hos et humant individ.
- 30 13. Antistof eller antigenbindingsfragment deraf ifølge et hvilket som helst af kravene 1 til 5 til anvendelse i en fremgangsmåde til behandling af lymfom.
14. En in vitro-fremgangsmåde omfattende trinnet administration til celler af en effektiv mængde af antistoffet eller antigenbindingsfragmentet deraf ifølge et hvilket som helst af kravene 1 til 5, hvor fremgangsmåden er udvalgt blandt følgende:
- (a) en fremgangsmåde til detektering af niveauet af CTLA4 i en prøve,

- (b) en fremgangsmåde til blokering af bindingen af human CTLA4 til human B7,
- (c) en fremgangsmåde til regulering af aktiviteten af human CTLA4 eller niveauet af human CTLA4,
- 5 (d) en fremgangsmåde til afhjælpning af immunsuppressionen på kroppen ved human CTLA4,
- (e) en fremgangsmåde til aktivering af T-lymfocytter, eller
- (f) en fremgangsmåde til forøgelse af ekspressionen af IL-2 i T-lymfocytter.

DRAWINGS




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21




Figure 22




Figure 23




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31




Figure 32




Figure 33




Figure 34